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Abstract
Atherosclerosis is a complex inflammatory disease in which oxidative stress is a
major protagonist in the development and progression of the atherosclerotic plaque. All
biochemical analysis studies of plaque over the past fifteen years have been carried out
on whole plaque with no attempt to localise sites of differing biochemical conditions.
This study set out to identify in oxidation levels and inflammatory markers in relation to
spatial localisation within the plaque.
Advanced plaque samples removed during endarectomy were obtained from the
Christchurch Hospital Department of surgery and were dissected into 3-5 mm sections
along the longitudinal axis prior to analysis. Samples were analysed for vitamin E,
neopterin, total cholesterol and markers of oxidative damage to protein and lipids.
Neopterin is a marker of inflammation as it is released by activated macrophages yet it
has never been measured in plaques. Initial analysis showed that the acid precipitation
method for removing protein from samples prior to HPLC neopterin analysis was causing
a significant loss in neopterin. A new acetonitrile based protein removal procedure was
developed.
Markers of oxidative stress and inflammation where shown to vary across the
length of an atherosclerotic plaque. This variation allows for localized incidences of high
and low radical flux and microenvironments of depleted antioxidants or areas in which
the prooxidative actions of molecular components are favoured. Significant correlations
were rarely seen in more then one plaque and trends found in the combined data set
generally did not hold true in individual plaques. This reflects upon the complexity of the
disease, especially at this advanced stage in which the biochemical morphology of
individual plaques is extremely diverse. Separation of the plaques into pre-, post-, and
bifurcation areas did produce some trends. These can be related to shear stress variations
in the blood flow; further investigations into the biochemical differences between these
areas may provide a better understanding of the growth and development of the
atherosclerotic plaque.
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1Introduction
Atherosclerosis
Atherosclerosis is the leading cause of morbidity and mortality in western society.
Statistics New Zealand lists cardiovascular disease as accounting for more then 40% of
deaths for 2000. Atherosclerosis has only recently been widely acknowledged as an
inflammatory disease (Libby et al. 2002), and progresses throughout the lifetime of the
individual. The early stages of the disease have been found to be present in infants
(Pesonen et al. 1990), although clinical manifestations usually only present themselves in
individuals older then fifty years (Milne et al. 2003). While the exact causes and
mechanisms of the disease are yet to be elucidated several “risk factors” have been
identified. These include age, gender, obesity, cigarette smoking, hypertension, diabetes
mellitus, and hyperlipidemia (Stocker and Keaney Jr 2004).
Atherosclerosis is a chronic condition characterised by the migration of
monocytes into the intima of arteries. These differentiate into macrophages which
become lipid loaded by the uptake of low density lipoproteins. Proliferation and death of
these cells contributes to a gradual hardening of the arteries and a narrowing of the vessel
lumen that impedes the blood flow. Over time the atherosclerotic lesion can become
unstable and suddenly rupture causing formation of a thrombus which can block blood
supply to vital organs such as the heart and brain. The result of which is heart attack and
stroke, respectively, and these can be collectively termed as cardiovascular disease.
The research described in this thesis has looked at the balance between oxidative
stress and antioxidant activity within the atherosclerotic plaque which drive plaque
development. Specifically the research involved the examination of plaques removed
from patients arteries and determined the concentration of a range of specific markers for
various known cell oxidative stress processes.
Plaque Development and Morphology
The normal arterial wall is composed of three defined layers; the tunica intima,
the tunica media and the arterial adventia (Saladin 2007). The innermost layer is the
2tunica intima and this is
composed of three further layers;
the endothelium, the intima and
the basement membrane (Figure
1).
The endothelial cells of
the endothelium act as a physical
and functional blockade from the
flowing blood. Endothelial cells
also play a regulatory role in
many arterial processes including
vascular tone and blood pressure
regulation, absorption of materials
and leukocyte trafficking
(Silverthorn 2004). These actions
are achieved in part through the
numerous mechanoreceptors on
the cell surface which respond to endothelial shear stress stimuli (Chatzizisis et al. 2007).
This induces a signaling cascade which leads to the activation of transcription factors that
ultimately modulates cell function and morphology (Chatzizisis et al. 2007).
The intima is normally comprised of a thin layer of loose connective tissue
between the endothelium and basement membrane (Saladin 2007). The basement
membrane is a layer of elastic tissue. Surrounding the tunica intima is the tunica media.
The media consists of layers of smooth muscle cells interspersed with an extracellular
matrix composed predominantly of elastin and collagen. The outermost layer of the
artery is the arterial adventia and is composed of connective tissue in a loose matrix of
elastin, smooth muscle cells, fibroblasts and collagen (Saladin 2007).
Lesion Initiation
The first observable stage of atherogenesis is commonly termed as a “fatty
streak” due to the sub-endothelial lipid deposition which is visible to the naked eye.
Lesions of this type can be commonly observed in children and by the third decade of life
can occupy as much as one-third of the surface of the aorta on autopsy examination
Figure 1: Composition of the normal
arterial wall.
Adapted from (Fox 1993)
3(Stary et al. 1995). However, the lesions are found only in certain specific locations of
the aorta.
The area of incidence for atherosclerotic lesions correlates strongly with locations
in which the blood experiences disturbed flow through the arteries such as at arterial
branch points and curvatures (Davies 2000). These areas are subjected to a localised
incidence of oscillating and low endothelial shear-stress which can produce different
functional characteristics in the endothelial cells of these regions (Chatzizisis et al. 2007).
These include increased production of leukocyte adhesion molecules, increased NADPH
oxidase activity and reduced nitric oxide synthesis; which can contribute to chronic
inflammation (Libby et al. 2002). Low endothelial shear stress also promotes the uptake,
synthesis and permeability of low density lipoprotein (LDL) (Chatzizisis et al. 2007).
Increased synthesis is due to the sustained activation of endothelial transcription factors,
caused by low shear stress, which up regulate LDL gene expression (Liu et al. 2002). The
transcription factors also promote the accumulation of monocytes via induction of
interleukin-8 (Yeh et al. 2004). The disrupted shear stress may also promote arterial
smooth muscle cells to produce lipoprotein binding proteoglycans which could contribute
to the increased uptake and retention of LDL in the intima of these areas (Libby et al.
2002).
The characteristic feature of fatty streaks is the presence of lipid filled
macrophages termed foam cells. Various hypotheses have been proposed to account for
the recruitment of monocytes and subsequent lipid loading of the differentiated
macrophages. The three major hypotheses have been termed as the response-to-injury;
the response-to-retention; and oxidative modification.
The response-to-injury hypothesis proposes that endothelium denudation initiates
atherogenesis leading to monocyte and platelet recruitment to the site of injury. These
release cytokines, vasoactive agents and growth factors which initiate inflammation.
Macrophages are recruited to the area as part of this inflammatory response where they
accumulate LDL to form foam cells and perpetuate the inflammation (Jang et al. 1993).
Recently, however, it has been shown that denudation of the endothelium is not common
and thus the theory has been refined proposing that endothelial dysfunction is capable of
initiating the atherogenic process through increased permeability to atherogenic
lipoproteins (Stocker and Keaney Jr 2004).
4The response-to-retention hypothesis suggests that lipoprotein retention, rather
than endothelial permeability, is the initiating factor in atherogenesis. The accumulation
of LDL is theorised to be a result of apolipoprotein B-100 motifs that mediate
proteoglycan binding and arterial factors which aid lipoprotein aggregation (Williams
and Tabas 1995). Aggregated LDL is readily internalised by macrophages and would
thus facilitate foam cell formation.
The oxidative modification hypothesis suggests that LDL itself is not atherogenic
until it has been modified. LDL that is caught in the subendothelial region can undergo
cell-mediated oxidation by the resident smooth muscle cells, endothelial cells and by
macrophages (Stocker and Keaney Jr 2004). Oxidised LDL (oxLDL) stimulates
monocyte chemotaxis and has been demonstrated to be taken up by macrophages in an
unregulated fashion via the scavenger receptor (Goldstein et al. 1979) thus supporting
foam cell formation.
The hypotheses outlined above represent the different theories as to what the
necessary initial events that generate the atherosclerotic lesion are. They should not be
viewed as mutually exclusive and undoubtedly each plays a part in lesion development.
The key events in lesion development and the early stages of progression are illustrated
in Figure 2.
Figure 2: Evolution of an atherosclerotic plaque.
Adapted from (Libby 2001).
5Lesion Progression
Whatever the initiating events, lesion progression is marked by migration and
proliferation of smooth muscle cells, the development of an acellular lipid pool which is
covered by a fibrous cap and mineral (calcium) deposition.
Continued cytokine release by foam cells, macrophages and T-cells along with
the release of growth factors by activated platelets leads to the proliferation and
migration of smooth muscle cells in the intima. Under normal conditions smooth muscle
cells serve to regulate wall tension; however, under these atherogenic conditions, smooth
muscle cells develop a synthetic phenotype (Jang et al. 1993). This change is
accompanied by further release of self-stimulating growth factors by the smooth muscle
cells themselves. This results in a gradual growth of the plaque over time.
Throughout the atherogenic process macrophages continue to be recruited into the
plaque and differentiate to the foam cell morphology. Foam cell death results in the
release of the accumulated lipid leading to the formation of an acellular lipid core. In
early lesions the cells undergo apoptotic death and a cleared by the normal phagocytotic
pathways (Harada et al. 1997, Tabas 2005). In more advanced stages of atherosclerosis
oxidative damage causes phagocytosis to be defective and the apoptosis of macrophages
leads to secondary necrosis and a pro-inflammatory response (Hegyi et al. 1996, Tabas
2005). This was demonstrated by the presence of extracellular apoptotic fragments in the
lipid core (Hegyi et al. 1996). Additionally, some of the extracellular lipid appears to be
derived directly from plasma derived lipoproteins aggregating in the extracellular matrix
(Stary et al. 1995).
The lipid core is usually covered by a thickened “cap” region composed of
fibrotic material. This reparative connective tissue forms in the regions of the intima
around the lipid core where the normal cell and intercellular matrix has been disrupted.
This extracellular matrix consists predominantly of collagen interspersed with smooth
muscle cells (Stary et al. 1995).
Another feature in some advanced atherosclerotic plaques is mineral deposition in
the form of calcium hydroxyapatite. Mineral deposits in atherosclerotic plaques have
been associated with elastic fibres and it has been suggested that vesicles in the
extracellular matrix derived from dead cells may serve as sites for calcification (Stary et
al. 1995). It has also been demonstrated that cholesterol and calcium phosphates can
accumulate together in lesions as crystal agglomerates (Laird et al. 2006). Alternatively,
6it has been suggested that this vascular calcification closely resembles the process of
osteogenesis, or bone formation, which involves the specific deposition of calcium by
cells (Abedin et al. 2004, Danilevicius et al. 2007).
Plaque Rupture, Thrombosis and Vascular Remodeling
Obstruction of arteries and gradual loss of blood flow due to growth of plaques
was once thought to be the main cause of clinical events; however, it is now clear that
rupture of the plaque leading to thrombis formation is the primary event leading to acute
vascular events such as myocardial infarction or stroke.
The integrity of the arterial wall is maintained by the synthesis and breakdown of
matrix proteins, mediated primarily by vascular smooth muscle cells and matrix
metalloproteinases (Galis and Khatri 2002). The fibrous tissues of the plaque supply the
structural integrity whereas the lipid core is weak and highly thrombogenic.
Unsurprisingly then, rupture risk factors include a thin fibrous cap and large pools of
lipid. Plaque rupture tends to occur at sights shown to have high circumferential stress
which is often at the shoulders of the fibrous caps (Arroyo and Lee 1999).
The shoulder areas also show a high level of infiltration by T-cells and
macrophages. Activated T-cells produce the cytokine interferon-γ which destabilises the 
plaque by preventing proliferation of smooth muscle cells and decreasing synthesis of
collagen fibrils (Van Der Wal and Becker 1999). Interferon-γ also activates macrophages
and thus stimulates the release of matrix metalloproteinases which degrade the
extracellular matrix and further destabilises the plaque (Arroyo and Lee 1999).
The degree of disturbance to the plaque which leads to thrombus formation can
differ substantially; from small surface erosions to deep tearing of the intima extending
into the lipid atheroma (Van Der Wal and Becker 1999). Depending upon the size of the
thrombus it can either be incorporated into the lesion, contributing to the rapid
progression of the plaque, or it can lead to an acute vascular event (stroke or .
The progression and stability of an atherosclerotic plaque is also determined in
part by the vascular remodeling brought about in response to the atherosclerosis
(Nakamura et al. 2001). This remodeling can take the form of expansive (outward)
remodeling or constrictive (inward) remodeling (Chatzizisis et al. 2007) (Figure 3).
7Figure 3: Vascular remodeling in atherosclerosis.
Adapted from (Chatzizisis et al. 2007)
Expansive remodeling is a process of arterial enlargement in response to
atherosclerosis that allows the lumen to remain preserved allowing the local endothelial
shear stress (ESS) to become normalised, reducing inflammation and leading to a
quiescent, asymptomatic plaque (Chatzizisis et al. 2007). However in some cases (~20%)
excessive expansive remodeling occurs to produce a region in which both the vessel and
the lumen are larger then normal neighboring areas (Sipahi et al. 2006). In these areas
low shear stress persists, promoting further plaque progression and vessel expansion and
subjecting the arterial wall to intense inflammation which leads to a thinly capped
fibroatheroma which is prone to rupture (Chatzizisis et al. 2007). Constrictive
remodeling occurs when fibroproliferative processes dominate leading to narrowing of
the lumen and is thought to be a direct result of plaque growth (Chatzizisis et al. 2007).
Constrictive remodeling may also develop through the process of wound healing in
response to micro-ruptures in high-risk plaques (Burke et al. 2001).
8Plaque Classification
The composition of advanced atherosclerotic lesions and their precursors have
been placed into histological classification by the American Heart Association (Stary et
al. 1995) and are summarized below. Many of these types can be found in different zones
across the length of an advanced atherosclerotic plaque.
Type I are the initial lesions consisting of isolated macrophage foam cells. Type
II lesions are fatty streaks and consist predominantly of intracellular lipid accumulation.
Types I and II are sometimes collectively termed as early lesions and are generally
present from the first decade of life.
Type III lesions are alternatively referred to as intermediate lesions and consist of
small extracellular lipid pools. Type IV lesions, or atheromas, are the first stage of
advanced lesions and histologically show a core of extracellular lipid. Type IV lesions
are generally present from the third decade of life on.
Type V lesions have extensive thickening of the intima by reparative fibrous
tissue layers, and are separated into three subclassifications: Va (fibroatheroma) has the
presence of fibrous connective tissue layers along with one or more lipid core; Vb
(calcific lesion) is a fibrous lesion which has been significantly calcified; and Vc (fibrotic
lesion) is a fibrous lesion which has little or no lipid core and little or no calcification.
Type VI, or complicated, lesions are characterised by some form of surface
defect, hematoma or thrombus superimposed upon the existing plaque histology.
Lesion type’s I-III are clinically silent and do not narrow the lumen or obstruct
the blood flow. Type IV lesions only obstruct blood flow minimally and generally
manifest no clinical symptoms. Type V lesions can either be clinically silent or overt
depending on the degree of artery obstruction and type VI lesions usually cause
significant obstruction of the arteries and are often symptomatic.
Oxidative Stress within the Atherosclerotic Plaque
Oxidative damage is considered to be a key factor in the initiation and
progression of atherosclerosis (Libby et al. 2002). Elevated levels of oxidised lipids,
proteins and sterols have been detected in all stages of human atherosclerotic plaques
9showing that oxidative events have occurred or are occurring within the plaque (Upston
et al. 2002). Oxidation of LDL is considered to be a crucial component of its unregulated
uptake and accumulation by macrophages. It is also toxic to cells thus contributing to
formation of the lipid core and decreasing plaque stability (Baird et al. 2005, Reid and
Mitchinson 1993).
Classical oxidised LDL (oxLDL) is formed through Fenton-type reactions with
reduced-metal ions and by cell-mediated oxidation (Figure 4) (Esterbauer et al. 1992).
The oxidation of LDL creates multiple atherogenic properties which are unobserved in
native LDL in addition to its uncontrolled uptake by macrophages. OxLDL is cytotoxic
to most cells and chemotactic for monocytes. It increases the expression of monocyte
chemotactic proteins on vascular cells, stimulates expression of vascular cell adhesion
molecules and induces macrophage proliferation. OxLDL is also inhibits cholesterol
export from macrophages, interferes with endothelium dependent relaxation of blood
vessels and is prone to aggregation (Esterbauer et al. 1992, Jessup et al. 2004).
Elevated levels of reactive oxygen species (ROS) and oxLDL can also contribute
to the formation of the acellular lipid core by triggering the death of macrophage foam
cells. The sources of oxidative stress within the plaque include cellular oxidants,
enzymatic oxidants, reduced metal ions and radicals generated on lipids and proteins
from initial oxidative events (Figure 4).
The predominant source of ROS is considered to be from the production of
superoxide (O2ˉ●) by macrophages. Superoxide dismutases to hydrogen peroxide
(reaction 1) which then reacts with reduced transition metals via the fenton reaction to
produce the highly reactive hydroxyl radical (reaction 2):
(1) 2O2ˉ● + 2H+ →  H2O2 + O2
(2) H2O2 + Fe2+/Cu+ →  Fe3+/Cu2+ + OH ˉ + ●OH
Atherosclerotic plaques have considerable amounts of catalytic iron and copper present
to facilitate this reaction (Minqin et al. 2005, Smith et al. 1992, Stadler et al. 2004).
Reduced iron can also catalyse the peroxidation of lipids directly via a fenton-type
reaction thus further contributing to the atherogenic environment (Fuhrman et al. 1994,
Gieseg and Esterbauer 1994, Murr et al. 1994).
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Figure 4: Oxidant generation within an atherosclerotic plaque.
Oxidants can be generated through the release of superoxide (O2ˉ●) which can dismutase
to hydrogen peroxide (H2O2). H2O2 can either form the hydroxyl radical (HO●) via the
fenton reaction using reduced metal ions or it can be converted to hypochlorous acid
(HOCl) by myeloperoxidase (MPO). HO● can directly attack the cell, oxidise low density
lipoprotein (LDL) or oxidise proteins to protein hydroperoxide (PrOOH). HOCl can
oxidise both lipid and proteins in LDL to form oxLDL or it can react with the cell plasma
membrane. One of the products of HOCl damage is the oxidation of tyrosine (Tyr) to
DOPA which occurs on protein amino acid residues. During oxidation of LDL to oxLDL
proteins (PrH) and lipids (LH) are oxidised to protein hydroperoxides (PrOOH) and lipid
peroxides (LOOH). Lipid peroxyl (LOO●) and lipid alkoxyl (LO●) radicals can cause
further lipid and protein oxidation. Macrophages potentially increase the pool of reduced
metal ions through the release of reduced thiols (R-SH) or direct electron transfer via the
plasma membrane electron transport complex (TPMET).
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Along with the formation of hydroxyl radicals hydrogen peroxide can
alternatively react with chloride ions to form hypochlorous acid (HOCl) when aided by
the enzyme myeloperoxidase (MPO). This heme protein is secreted by activated
phagocytes during inflammation (Heinecke 2002). Active MPO has been shown to
present within the atherosclerotic lesion (Daugherty et al. 1994) and high levels of MPO
are associated strongly with coronary artery disease (Zhang et al. 2001).
Macrophages further contribute to the oxidative environment of the plaque
through the release of reductants. The transplasma membrane electron transport system
(TPMET) of macrophages transfers electrons to external ferric and cupric ions enabling
participation in the fenton reaction (Baoutina et al. 2001). This recycling of metal ions to
their reduced forms is further enhanced by reduced thiol release by macrophages
(Graham et al. 1994).
The polyunsaturated fatty acids (PUFAs; LH), which are a large component of
LDL and cell membranes, are readily oxidised by radicals (R●) (reaction 3) to give a lipid
radical (L●) which immediately reacts with molecular oxygen (reaction 4). This lipid
peroxidation is particularly damaging as it creates a self-perpetuating chain-reaction
through creation of the lipid peroxyl radical (LOO●) which can oxidise neighboring
PUFAs (reaction 5). The resultant lipid hydroperoxides (LOOH) can break down to
produce further radicals and a range of other compounds including aldehydes (reaction 6)
which can diffuse from the original site thus spreading the damage (Cheeseman and
Slater 1993). The presence of oxidised lipids in all stages of atherosclerotic plaques have
been reported on widely (Carpenter et al. 1995, Suarna et al. 1995, Yia-Herttuala et al.
1989)
(3) LH + R● →  L● + RH
(4) L● + O2 → LOO●
(5) LOO● + L'H → LOOH + L'●
(6) LOOH →   LO●, LOO●, aldehydes
Proteins are also vulnerable to oxidation. Protein bound-DOPA (PB-DOPA),
dityrosine, protein carbonyls, protein hydroperoxides and protein bound-chlorotyrosine
have all been identified in plaques (Fu et al. 1998, Upston et al. 2002, Woods et al.
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2003). The action of hydroxyl radicals and hypochlorous acid on protein tyrosine
residues produces PB-DOPA (Gieseg et al. 1993, Sutherland et al. 2003). PB-DOPA is
able to perpetuate oxidative stress by reducing copper and iron ions making them
available to participate in the fenton reaction and thus catalysing the production of
radicals (Morin et al. 1998).
Protein hydroperoxides are the primary product generated from the attack of
hydroxyl radicals on proteins (Simpson et al. 1992). In LDL the formation of protein
hydroperoxides on the apoB100 protein moiety depends upon the formation of the
peroxyl radical in the lipid phase of the LDL molecule (Gieseg et al. 2003). Protein
hydroperoxides can cause considerable disruption to normal cell functions as they are
able to deactivate enzymes and have been demonstrated to cross-link with DNA (Gebicki
1997). They are also capable of depleting antioxidant pools through the oxidation of
glutathione (GSH) and ascorbate (Gebicki 1997, Kappler et al. 2007, Simpson et al.
1992). Upon breakdown protein hydroperoxides form protein carbonyls which are a
relatively unreactive end-product that is normally eliminated by proteolysis (Davies et al.
1999).
Antioxidants within the Atherosclerotic Plaque
Given that oxidative stress plays a pivotal role in the formation of the
atherosclerotic plaque it is equally important to examine antioxidant content. The
antioxidant enzymes; glutathione peroxidase, glutathione reductase and superoxide
dismutase and the non-proteinaceous antioxidants; vitamin C, uric acid, vitamin E and
ubiquinol-10 have all been measured within atherosclerotic plaques (Stocker and Keaney
Jr 2004). The presence of these antioxidants does not preclude oxidative damage.
Temporal and spatial variation in concentrations of antioxidants may allow the sustained
oxidative stress to induce damage.
Vitamin E and Ascorbate
The lipid soluble antioxidant α-tocopherol, which is the most biologically active
isoform of vitamin E, is localised in membranes and lipoproteins and is the major
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antioxidant present in LDL. Given the importance of LDL oxidation to plaque formation;
the content and antioxidant activity of α-tocopherol within atherosclerotic lesions is of
considerable interest.
α-Tocopherol (α-TocH) reacts rapidly with lipid peroxyl radicals and interrupts
the chain reaction of lipid peroxidation (reaction 7). This forms a relatively stable
tocopheroxyl radical (α-Toc●) which will normally react with a second radical species to
produce stable non-radical products (reaction 8). However, in cases of low radical flux,
the tocopheroxyl radical can react with PUFAs by extracting a hydrogen to regenerate
tocopherol and produce a new lipid radical (reaction 9). This effect is referred to as
tocopherol mediated peroxidation (TMP) and only occurs when there are no lipid peroxyl
radicals for the tocopheroxyl radical to react with. This is because of the comparatively
slower reaction rate between the tocopheroxyl radical and unoxidised lipids (Bowry and
Stocker 1993). The new lipid peroxyl radical generated can consequentially initiate a new
autoxidation chain reaction.
(7) α-TocH + LOO● →  α-Toc● + LOOH
(8) α-Toc● + LOO● → unreactive + LOOH (106 – 107 )
tocopherlylquinone
(9) α-Toc● + LH →  α-TocH + L● (100 – 104 )
Even in cases of low radical flux TMP can be protected against through reaction
with co-antioxidants such as ascorbate and ubiquinol-10 which can transfer the radical to
the aqueous phase (Bowry and Stocker 1993). Ascorbate does this directly across the
phase boundary, whereas the lipophilic ubiquinol-10 radical is assumed to react with
molecular oxygen to give water soluble superoxide (Bowry and Stocker 1993). The
detection of these co-antioxidants along with α-tocopherol in atherosclerotic lesions
(Suarna et al. 1995) may restrict the relevance of TMP in vivo.
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The radical scavenger ascorbate is one of the major intra- and extra-cellular
water-soluble antioxidants. Along with radical scavenging and it role as a co-antioxidant
to vitamin E, ascorbate can also break down protein hydroperoxides to unreactive
hydroxylated amino acid residues (Simpson et al. 1992). Ascorbate can also inhibit
copper- and cell-mediated oxidation of LDL which could potentially lower the quantity
of oxLDL in plaques (Esterbauer et al. 1989, Retsky et al. 1993, Retsky and Frei 1995,
Stait and Leake 1994). However, ascorbate also has the ability to reduce metal ions
which can be a source of oxidative stress within the plaque environment (Stait and Leake
1994).
7,8-Dihydroneopterin and Neopterin
7,8-Dihydroneopterin (78NP) is released from primate macrophages following
stimulation by the cytokine γ-interferon (Gieseg et al. 2007, Muller et al. 1991). γ-
Interferon upregulates the action of GTP-cyclohydrolase which catalyses the conversion
of GTP to 7,8-dihydroneopterin triphosphate. Primate macrophages contain low levels of
the enzyme 6-pyruvoyltetrahydropterin synthase which is the next enzymatic step
towards 5,6,7,8-tetrahydrobiopterin. Instead the 7,8-dihydroneopterin triphosphate is
converted to 78NP by intracellular phosphotases and diffuses out of the cells (Schoedon
et al. 1987) (Figure 5).
Neopterin is the highly fluorescent compound produced by the oxidation of 78NP
by hypohalous acids (Gieseg et al. 2000, Widner et al. 2000) (Figure 5) and is used as
a marker of inflammation and the immune response (Huber et al. 1983). The level of
neopterin in biological fluids is measured either by ELISA or by HPLC with
fluorescence detection. Though the initial purchase price of a HPLC is relatively high
compared to ELISA equipment, the cost in consumables for each individual sample is
relatively inexpensive making it the method of choice in many research laboratories.
Neopterin measurement by HPLC is discussed in more detail in the results and
discussion of this thesis.
Measurement of plasma and urine neopterin have been used in the clinical
management of numerous diseases including HIV infection (Fuchs et al. 1989),
autoimmune diseases (Reibnegger et al. 1986), bacterial infections (Strohmaier et al.
1996) and post-operative transplant patients (Margreiter et al. 1983). In relation to heart
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Figure 5: Generation and oxidation of 7,8-dihydroneopterin.
γ-Interferon stimulation of macrophages causes the enzymatic breakdown of intracellular
GTP to 7,8-dihydroneopterin which can either be oxidised to the highly fluorescent
neopterin by HOCl of to 7,8-dihydroxanthopterin by peroxyl and hydroxyl radicals.
disease, serum neopterin is elevated in atherosclerosis and correlates with the extent of
the disease (Garcia-Moll et al. 2000, Tatzber et al. 1991, Weiss et al. 1994). The
elevation is even more pronounced shortly after the onset of symptoms in patients with
unstable angina and acute myocardial infarction (Auer et al. 2001, Schumacher et al.
1997).
Despite the clinical utility of neopterin as a marker of inflammation, the
physiological role of both neopterin and 78NP is yet to be fully understood. Evidence for
both pro- and antioxidative activities and cell signaling activities have been produced in
numerous in vitro studies.
Antioxidative properties have been attributed to 78NP, although the first indicator
of this action was demonstrated in another reduced neopterin derivative,
tetrahydroneopterin, which showed high superoxide scavenging abilities in
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xanthine/xanthine oxidase and phorbol myristate acetate stimulated macrophage systems
(Kojima et al. 1992). 78NP was subsequently shown to have similar radical scavenging
abilities through inhibition of chemiluminescence induced by hydrogen peroxide and
chloroamine T (Weiss et al. 1993).
The ability of 78NP to protect LDL from oxidation was shown by an increased
lag time in LDL oxidation mediated by Cu2+ ions or aqueous peroxyl radicals (Gieseg et
al. 1995). Low micromolar concentrations of 78NP have also been demonstrated to
inhibit cell-mediated oxidation of LDL by THP-1 cells; a human derived monocyte-like
cell line (Firth et al. 2007, Gieseg and Cato 2003).
78NP has also been shown to protect more complex target cells from free radical
damage. Haemolysis of erythrocytes by hypochlorite and peroxyl radicals was prevented
by 78NP (Gieseg et al. 2001a) and 78NP also provided a protective antioxidant effect to
U937 cells (another monocyte-like cell line) against fenton generated reactive ROS and
hypochlorite (Gieseg et al. 2001b) and TNF- α mediated apoptosis (Baier-Bitterlich et al.
1995). 78NP was also able to inhibit the toxic effects exerted by oxidised LDL on other
cells by inhibiting thiol loss in U937 cells (Baird et al. 2005). This has lead to the
hypothesis that 78NP is produced to protect the macrophages from oxidants during
inflammation (Gieseg et al. 1995, Gieseg et al. 2000, Gieseg et al. 2007).
At much higher concentrations (>5mM) 78NP has been demonstrated to
significantly enhance the TNF-α mediated apoptosis of U937 cells (Baier-Bitterlich et al.
1995) and neuronal NT2/HNT cells (Spottl et al. 2000). However, it is unlikely that
78NP would reach these concentrations in vivo as this is near its solubility limit. At 78NP
concentrations of 1 mM or more apoptosis is induced in human peripheral blood T cells
(Wirleitner et al. 2003). This programmed cell death could be mediated by the addition of
the antioxidants catalase and superoxide dismutase and also by addition of a metal
chelator. Apoptosis also occurs at these levels in Jurkat T cells (Baier-Bitterlich et al.
1996, Wirleitner et al. 1998, Wirlettner et al. 2001) and this has been shown to occur via
the redox-sensitive Bcl-2 pathway (Enzinger et al. 2002a).
The mechanisms of this prooxidative effect of 78NP all involve direct generation
of ROS due to the reducing power of 78NP (Oettl et al. 2004). This may be due to the
reduction of metal ions within the cell media increasing ROS formation (Gieseg et al.
2007). This scenario only presents itself when the concentration of 78NP is extremely
high and in protein-free media, as proteins are themselves excellent radical scavengers,
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and thus may be of limited relevance within the atherosclerotic plaque (Gieseg et al.
2007).
Neopterin has also showed pro-apoptotic properties with low micromolar
concentrations inducing apoptosis in rat alveolar epithelial cells (Schobersberger et al.
1996). Neopterin has been shown to exhibit enzyme inhibition action with the
competitive inhibition of NADPH oxidase (Kojima et al. 1993) and has also been shown
to stimulate iNOS gene expression and nitric oxide production in vascular smooth muscle
cells and the synthesis of TNF-α (Hoffmann et al. 1998). It has also been shown to
increase the singlet oxygen produced by MPO while decreasing other reactive species
such as HOCl (Razumovitch et al. 2004). Additionally neopterin has been shown to
inhibit ATP-induced calcium release in alveolar epithial cells (Hoffmann et al. 2002). As
there is little evidence that neopterin is toxic to macrophages it has been hypothesised
that neopterin augments the cytotoxic potential of activated macrophages (Hoffmann et
al. 2003).
A hypothetical model for the actions of 78NP and neopterin within the
atherosclerotic plaque has been proposed in which 78NP and neopterin exist in a
pro/antioxidative balance (Gieseg et al. 2007). In the early stage of plaque formation
78NP would slow or inhibit oxLDL formation and prevent the oxLDL and hydroxyl
radical damage of macrophages, which may contribute to the stabilization of foam cells.
During the chronic inflammation of atherosclerosis lowered levels of 78NP would shift
the redox balance to a pro-oxidative state leading to oxLDL formation and cell
necrosis/apoptosis. Alternatively high levels of 78NP brought about by intense
inflammation which would also result in increased HOCl formation would elevate
neopterin levels which would switch off MPO activity and could trigger neutrophil
apoptosis.
Objectives of Study
The aim of this study is to examine oxidative damage and antioxidant content of
atherosclerotic plaques and assess the relationship of these parameters to each other and
to their localisation within the plaque.
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A pilot study on atherosclerotic plaques performed previously in this lab has
demonstrated the presence of neopterin in two atherosclerotic plaques and measured the
concentrations of this, vitamin E and markers of protein and lipid oxidation across the
length of the plaque. Prior to this measurement of neopterin has never been performed in
atherosclerotic plaques. This study expands upon this data set allowing more powerful
comparisons to be made.
All biochemical analysis studies of plaque over the past fifteen years have been
carried out on whole plaque with no attempt to localise sites of differing biochemical
conditions. This study allows for the identification of trends in oxidation levels and
inflammatory markers in relation to spatial localisation within the plaque. Also many
previous studies on plaque material remove matrix proteins by centrifugation and in
doing so remove much of the analytes. Experimental methods employed in this study
allow the analyses to be carried out on full plaque homogenate without the removal of
important analytes.
With relation to measurement of neopterin in the plaque; weaknesses in the
current method of neopterin and 78NP measurement in serum and tissue samples are
addressed by the development of a new method for the precolumn treatment of the
sample prior to HPLC analysis.
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Materials and Methods
Materials
All chemicals and reagents used for this research were of analytical grade or
better. Water was deionised and ultrafiltered using a NANOpure ultrapure water system
(Barnstead/Thermolyne; Iowa, USA). All solutions were prepared in nanopure water.
Salt-containing HPLC mobile phases were vacuum filtered through a 0.45 µM membrane
and all HPLC mobile phases were degassed via sonication followed by online degassing.
Chemicals and Reagents
α-Tocopherol Sigma Chemical Co.; St. Louis, MO, USA
1,1,3,3-Tetramethoxypropane Sigma Chemical Co.
2,4-Dinitrophenyl hydrazine (DNPH) Sigma Chemical Co.
2-thiobarbituric acid (TBA) Sigma Chemical Co.
3,4-Dihydroxyphenylalanine (DOPA) Sigma Chemical Co.
7,8-Dihydroneopterin (78NP) Schricks Laboratory; Switzerland
Acetone Merck Ltd.; Darmstadt, Germany
Acetonitrile Mallinckrodt Baker B.V.; Holland
Argon gas BOC Gasses; NZ
Bicinchoninic acid (BCA) protein Pierce; Illinois, USA
determination kit
Bovine serum albumin (BSA) Sigma Chemical Co.
Butylated hydroxytoluene (BHT) Sigma Chemical Co.
Cholesterol reagent Roche Diagnostics; USA
Di-ammonium hydrogen orthophosphate BDH Laboratory Supplies; Poole, England
Diethyl ether Merck Ltd.
Ethanol Scharlau Chemie S.A.; Barcelona, Spain
Ethyl acetate Merck Ltd.
Ethylenediaminetetraacetic acid (EDTA) BDH Laboratory Supplies
Guanidine hydrochloride (GuHCl) Sigma Chemical Co.
Hexane Asia Pacific Specialty Chemicals
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Hydrochloric acid (HCl) Merck Ltd.
Iodine BDH Laboratory Supplies
L-Ascorbic acid BDH Laboratory Supplies
Mercaptoacetic acid Sigma Chemical Co.
Methanol Scharlau Chemie S.A.
Neopterin Schricks Laboratory
Nitrogen gas Southern Gas Services Ltd.; NZ
Orthophosphoric acid 85% BDH Laboratory Supplies
Perchloric acid (PCA) BDH Laboratory Supplies
Phenol Sigma Chemical Co.
Potassium iodide Merck Ltd.
Sodium dihydrogen orthophosphate Scharlau Chemie S.A.
Trichloroacetic acid (TCA) Sigma Chemical Co.
Trifluoroacetic acid (TFA) Sigma Chemical Co.
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Methods
Sample Collection and Preparation
Plasma Samples
Blood samples were obtained by venipuncture from ten randomly selected
septicaemia patients and five healthy control volunteers. Septicaemia patients were
undergoing amino glycoside therapy and blood samples were collected as part of their
routine monitoring from the Department of Toxicology at Christchurch Hospital. Plasma
was prepared by centrifugation and stored at -80°C until analysis for neopterin and total
neopterin analysis.
Plaque Samples
Plaques were removed from the carotid arteries of patients undergoing carotid
endarectomies at the Department of Surgery at Christchurch Hospital. The plaque was
placed on ice for transport to the Free Radical Biochemistry Laboratory where it was
stored at -80°C. Written consent was obtained from the patients prior to surgery for
analysis of their plaques and for the provision of clinical notes to the researcher. Plaques
were assigned an identification number based on the patient’s initials and date of surgery;
this number is given at the beginning of the data for the individual plaques. For purposes
of this publication plaques were arbitrarily assigned an alphabet letter for identification
throughout the publication.
Prior to analysis the plaque was thawed and photographed. It was then dissected
into sections of approximately 3-5 mm and the transverse view of the individual sections
was photographed. The sections were numerically labeled in order starting proximal to
the bifurcation. Each section was assigned to a zone (pre-bifurcation, bifurcation and
post-bifurcation) depending on its localisation in the intact plaque. The plaque as a whole
was classified based on qualitative visual observation by the researcher (heavily
calcified, thrombosed or neither).
Weights of the sections were recorded prior to homogenisation with a tissumizer
in 5 mL water and 50 µL each of 20 mg/mL BHT (in methanol) and 100 mg/mL EDTA
(pH 7.4). The total volume of homogenate was recorded before samples were aliquoted
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for analysis of carbonyls, cholesterol, dityrosine, DOPA, neopterin, protein, TBARS and
vitamin E.
HPLC Analyses
High Performance Liquid Chromatography (HPLC) measurements were
performed using a Shimadzu Sil-10A HPLC system with temperature controlled
autosampler and RF-10Axls fluorescence detector (Shimadzu Corporation; Japan). Peak
areas were quantified using the Shimadzu CLASS-VP software package.
Neopterin and Total Neopterin
Neopterin was detected in both plaque and plasma samples by its native
fluorescence at 438 nm, excitation 353 nm. Total neopterin (neopterin plus 78NP) was
measured by first oxidising the 78NP to neopterin (Werner et al. 1987). Two differing
sample preparation methods were employed for neopterin measurement; the original
method involving acid precipitation of proteins using TCA (Werner et al. 1987), and a
new method which employed acetonitrile for protein precipitation developed as part of
this research program. Due to the limited amount of plaque homogenate available,
plaques were only measured by either the TCA method or the acetonitrile method.
TCA Method
100 µL of sample was combined with 10 µL of 6 µM ascorbate and 10 µL of
50% trichloroacetic acid (TCA) followed by vortex then centrifugation ( 4°C and 10 300g
for 15 min ); 100 µL of the acid supernatant was then placed in an autosampler vial for
HPLC analysis.
Acetonitrile Method
100 µL of sample was combined with 100 µL of 100% acetonitrile, vortexed and
centrifuged (40C and 10 300g for 10 min). 100 µL of the supernatant was then transferred
to an autosampler vial for HPLC analysis.
Total Neopterin
For total neopterin analysis an oxidation step was included to convert 78NP to
neopterin for detection following the protein precipitation and centrifugation steps. After
following the methods of protein precipitation outlined above 10 µL of acidic iodide
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solution (5.4% I2 / 10.8% KI in 1 M HCl) was added to supernatant and incubated for 20
minutes at room temperature in the dark. 10 µL of 6 μM ascorbate was added to oxidise
the iodine before centrifugation of the samples (40C and 10 300g for 5 min). With the
TCA treatment method for total neopterin analysis the ascorbate was not added before
protein precipitation as it is when measuring neopterin alone but added subsequent to
iodide oxidation of 78NP as described above.
HPLC Analysis
10 μL of sample was injected onto a Phenomenex Develosil reverse phase ODS-
MG-5 4.2 x 250 mm column and developed isocratically with a mobile phase of 5%
methanol in 20 mM ammonium phosphate pH 6.0 pumped at 1 mL/minute (Gieseg et al.
2001a). The eluting neopterin was detected by fluorescence at excitation 353 nm and
emission 438 nm. The column temperature was maintained at 35°C. The concentration
and identity of the eluted neopterin was confirmed by comparison to a commercial
standard of 1µM neopterin (Schricks Laboratory; Switzerland) and quantified by peak
area.
TBARS
The TBARS assay is an indirect measure of lipid peroxidation. The reaction of 2-
thiobarbituric acid (TBA) with the lipid hydroperoxide breakdown product,
malondialdehyde (MDA), produces a pink adduct which can detected fluorometrically
(Draper et al. 1993).
100 µL of plaque homogenate was combined with 50 µL of 150 mM phosphoric
acid and a further 10 µL of 20 mg/mL BHT (in methanol). The samples were then stored
at -80°C while awaiting analysis.
The 42mM TBA reagent is prepared fresh on the day of analysis by dissolving
TBA in water while heating to approximately 50°C, after which it is allowed to cool
before use. After thawing, samples underwent a 30 minute incubation at 95°C in the
presence of 50 µL of 42 mM TBA reagent. The samples were then cooled on ice and
centrifuged (4°C, 10 300g, 10 minutes).
20 µL of supernatant was injected onto a Phenosphere reverse phase C-18 4.6 x
150 mm 5 µm column and developed isocratically with a mobile phase of 45% methanol
in 50 mM sodium dihydrogen phosphate pH 6.8 pumped at 1 mL/minute. The eluting
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TBARS were detected by fluorescence at excitation 525 nm and emission 550 nm. The
column temperature was maintained at 30°C.
The concentration and identity of the eluted TBARS was confirmed by
comparison to the peak areas of 0µM and 1µM MDA standards reacted with TBA as
outlined above. The MDA standard was prepared from 6mM 1,1,3,3-
tetramethoxypropane in 2:3 ethanol:water, subsequently diluted in water to the
appropriate concentrations which is thermolytically hydrolysed during the 95°C
incubation. Phosphoric acid and BHT were included in the standards as per the
experimental samples.
Vitamin E
α-Tocopherol (vitamin E) was determined by reverse phase HPLC with
fluorescence detection of hexane extracts of plaque homogenate (Esterbauer et al. 1987,
Gieseg et al. 1995).
100 µL of plaque homogenate was Gieseg et al. 1995a combined with a further
400 µL of water, 10 µL of 100 mg/mL EDTA (pH 7.4) and 25 µL of 20 mg/mL BHT in
methanol. Protein was precipitated with 500 µL of ethanol and the vitamin E was
extracted into 2 mL of hexane (60 second vortex). Samples were stored at -80°C while
awaiting analysis. Upon thawing samples were vortexed for a further 60 seconds before
centrifugation (4°C, 1 600g, 5 minutes) to maximise phase separation. 1400 µL of the
upper hexane phase was dried under nitrogen gas and the resulting residue was
redissolved in 50 µL of methanol for HPLC analysis.
20 µL of sample was injected onto an Econosphere reverse phase C-18 4 x 125
mm 5 µm column and developed isocratically with a mobile phase of 100% methanol at
1 mL/minute. The eluting Vitamin E was detected by fluorescence at excitation 292 nm
and emission 335 nm. The column temperature was maintained at 35°C. The
concentration and identity of the eluted vitamin E was confirmed by comparison to a
3µM Vitamin E standard (Sigma Chemical Co.; USA) and quantified by peak area.
DOPA and Dityrosine
DOPA and dityrosine are oxidation products of the amino acid tyrosine and thus
are a measure of protein oxidation. Protein-bound DOPA and dityrosine are measured by
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their native fluorescence via reverse phase gradient HPLC following the acid hydrolysis
of the protein into free amino acids (Gieseg et al. 1993).
In glass Durham tubes 100 µL of plaque homogenate was mixed with 900 µL of
glacial acetone and placed on ice for 10 minutes before centrifugation. The protein pellet
was washed with 500 µL of glacial diethyl ether and centrifuged as above. The diethyl
ether was drained off with any residual removed under vacuum leaving the pellet ready
for acid hydrolysis. This procedure removes all free lipid, salt and carbohydrates which
can interfere with the analysis.
Samples were placed into Pico-Tag reaction vials (Millipore; USA) containing 1
mL of 6 M HCl with 1% (w/v) phenol and 50 µL mercaptoacetic acid. Vials were flushed
with argon gas for 10 minutes and then evacuated using a vacuum pump. Samples were
incubated for 16 hours at 110°C. The resulting hydrolysis residue was dried in a speed
vac and then redissolved in 200 µL of 0.1% TFA for HPLC analysis.
10 µL of sample was injected onto a Phenomenex reverse phase C-18 250 x 4.6
mm 5 µm column with a mobile phase of 0.1% TFA pH 2.5 pumped at 1 mL/minute.
The sample was separated by a gradient which started at 0% Acetonitrile rising to 5%
over 10 minutes. The acetonitrile was increased to 10% over the next 4 minutes and
further increased to 50% over the next 4 minutes. The acetonitrile content was then
decreased to 1% over seven minutes before finally decreasing the acetonitrile to 0% over
the next 7 minutes.
The eluted DOPA and dityrosine were detected by fluorescence at excitation 280
nm and, initially, emission 320 nm for DOPA detection. After 13 minutes the emission
wavelength was changed to 410 nm for dityrosine detection. The column temperature
was maintained at 35°C. The concentrations and identities of the eluted DOPA and
dityrosine were confirmed by being compared to a commercial standard (Sigma
Chemical Co.; USA) and a previously prepared laboratory standard (Amado et al. 1984)
respectively, and quantified by peak area.
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UV Visible Spectrometry
Carbonyls
Carbonyls are a general measure of protein oxidation. The reaction of carbonyls
with 2,4-dinitrophenyl hydrazine (DNPH) forms a carbonyl-DNPH derivative with
maximal absorbance at 360 nm (Quinlan et al. 1994).
200 uL of plaque homogenate was combined with either 1 mL of 10 mM DNPH
in 2 M HCl or 1 mL of 2 M HCl only to serve as a blank. All samples were incubated
with gentle shaking for 90 minutes at 37°C and were then cooled on ice in the presence
of 1 mL of 28% TCA. Samples were centrifuged (4°C, 4 100g, 10 minutes) and the
resulting pellet was washed twice with 5 mL of 1:1 ethanol:ethyl acetate. The dried pellet
was resuspended in 1 mL of 6 M guanidine hydrochloride in 2 M HCl and incubated for
one hour at room temperature in the dark to allow colour to develop.
Samples were centrifuged (4°C, 4 100g, 5 minutes) and the absorbancies of the
supernatant were recorded at 360 nm. Blank values were subtracted from the
corresponding DNPH treatment value and the carbonyl concentration was calculated
using an extinction co-efficient of 21,000 cm-1.M-1 (Quinlan et al. 1994).
Total Cholesterol
Total cholesterol content was determined by incubation of 10 µL of plaque
homogenate with 1 mL of enzymatic “Chol. MPR 2” reagent (Roche Chemicals) for 30
minutes. Absorbancies were recorded at 500 nm against a cholesterol reagent blank and
cholesterol content calculated as per the manufacturers’ instructions.
Protein
Protein concentration was determined used a bicinchonic acid (BCA) protein
determination kit: “working reagent” was freshly prepared by combining Reagent A
(sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.1 M sodium
hydroxide) and Reagent B (4% hydrated copper sulphate) in a 50:1 ratio.
Plaque homogenate was diluted with water to appropriate levels and 50 µL was
mixed with 1 mL of “working reagent”. Samples were incubated for 30 minutes at 60°C
with gentle shaking, after which the samples were placed on ice to halt the reaction.
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Absorbancies were recorded at 562 nm and the protein concentration was determined
from a standard curve of commercial BSA supplied with the kit.
Statistics
All analyses were carried out on triplicate samples (unless otherwise stated).
Concentrations given are the mean of triplicates with standard error shown as a way one
error bar.
Statistics were performed with the software packages Statistica (version 7.1;
StatSoft, Inc., USA) and Prism (version 4.0; Graphpad Software, USA).
Between sample comparisons were performed by one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test to designate significant
variations between means. Significance levels are indicated within the text.
Factorial ANOVA was also performed on plaque data; prior to which the data
sets were assessed for homogeneity of variances and normality. Data not conforming to
these assumptions was transformed accordingly before analysis. Analyses containing
significant variation was presented as the least square of the mean (LS mean) by the
relevant factor with error bars denoting the 95% confidence intervals.
Pearson correlation analyses were performed on plaque data and significant
relationships were presented in tabular form.
Ethics
Ethics approval for the analysis of plaque and access to clinical patient data was
given by the Upper South Ethic Committee; ethics approval number 01/04/036. All blood
samples were surplus to clinical requirements and were anonymised before release for
neopterin analysis as part of the diagnostic laboratory ethics approval for assay validation
or establishing a reference range. This study was been approved of by the Upper South A
Regional Ethics Committee; ethics approval number URA/07/16/EXP.
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Results
Neopterin Analysis Development
HPLC analysis of plasma or tissue requires the removal of proteins. Original
methods used ion exchange solid phase extraction to collect and concentrate the
neopterin (Fukushima and Nixon 1980, Werner et al. 1987), but with changes to solid
phase manufacturing these methods appear to have become unreliable and technically
demanding. The more common methods now employed remove sample proteins by acid
precipitation prior to HPLC analysis. However, under acidic conditions, 7,8-
dihydroneopterin (78NP) is oxidised to neopterin with varying yield (Figure 6) (Werner
et al. 1987). This oxidation can be partially prevented by the addition of ascorbate prior
to acid precipitation but is not completely effective (Figure 6). Acetonitrile was assessed
as an alternate, non-acidic reagent for protein precipitation.
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Figure 6: Oxidation of 78NP to neopterin by TCA.
Standard solutions of 1µM 78NP were analysed for neopterin content. The samples were
left untreated, were fully oxidised to neopterin using an acidic iodide solution (iodide
oxidised) or 100µl of standard was treated with 10µl of 50% TCA (TCA treated) or 10µl
of 50% TCA and 10µl of 6µM ascorbate (TCA + ascorbate) prior to HPLC analysis.
Values shown represent the mean + SE of triplicates.
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Figure 7: HPLC chromatograms of plasma neopterin.
HPLC chromatograms of neopterin from plasma samples treated prior to injection with
either A) TCA or B) acetonitrile. Samples were taken from a selected septicaemia
patient. Note the scale in B is 0.0 to 0.006 compared to 0.0 to 0.0025 in A.
The use of acetonitrile to remove sample proteins markedly improved the
resolution and signal to noise ratio seen during HPLC compared to TCA treatment
(Figure 7). TCA treated samples also showed a number of additional contaminant peaks
during chromatography. With the acetonitrile treated samples, neopterin was consistently
observed to elute one minute sooner than the neopterin from TCA treated samples. This
is due to the increase in organic solvent in the samples from the addition of 50%
acetonitrile. The neopterin peak identity was confirmed by spiking plasma samples with
authentic neopterin.
In the acetonitrile treated sample’s chromatogram (Figure 7B), the neopterin peak
area is smaller than that seen in the chromatogram of the TCA treated sample (Figure
7A). This is due to the dilution of sample which occurs with the acetonitrile treatment.
When dilution factors are taken into account the apparent concentration of neopterin in
the plasma from the TCA treated sample is 31.4 nM and in the acetonitrile treated sample
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55.3 nM. This apparent increase in neopterin levels with acetonitrile treatment was
generally observed with all plasma and tissue samples examined. This increase in
neopterin with acetonitrile treatment was not observed using protein free buffers
suggesting the effect was due to the actual precipitation of the protein.
The linearity of the acetonitrile treatment and analysis was confirmed by
measuring different concentrations of neopterin between 0.05 and 2 µM. The calibration
curve (y = 1.019x – 0.015) was linear over this range with a correlation coefficient of r2 =
1.00. Within-run precision, evaluated by ten consecutive injects from the same plasma
sample, and between-run precision, evaluated by injects on six separate days from the
same plasma pool, showed repeatability of the assay is good (within-run CV% < 2.9,
between-run CV% < 3.8).
Analysis of ten septicemia patients and five apparently healthy controls showed
the acetonitrile treatment consistently returned higher levels of neopterin and total
neopterin than the acid based treatment (Figure 8 & Figure 9). The acetonitrile
precipitation treatment gave on average a 20 nM increase in neopterin levels compared to
that obtained using TCA for both the healthy controls and septicemia patients (Figure 8A
& Figure 9A). However, with total neopterin analysis (78NP + neopterin), where the
78NP is oxidised to neopterin, the increase in neopterin due to the acetonitrile treatment,
compared to TCA, was less consistent. With healthy controls acetonitrile treatment gave
on average a 50% increase in total neopterin compared to TCA, but this increase ranged
from 4.3 nM to 12.9 nM (Figure 9B).
With septicemia patients the measured total neopterin level also increased with
acetonitrile treatment (Figure 9B) but by approximately 100% compared to the TCA
treated samples. The size of this increase ranged from 15 nM to 120 nM.
TCA treatment shows a picture of healthy subjects having the majority of the
pterin as 78NP (75%) (Figure 10). In the septicemia patients, this ratio is reversed where
the majority of the pterin is present as neopterin (83%).
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Figure 8: Effect of sample preparation on plasma neopterins from septicaemia
patients.
Plasma neopterin (A) and total neopterin (B) concentrations for ten septicaemia patients.
Samples were prepared for analysis using either acetonitrile (■) or TCA (□) for protein
precipitation before HPLC analysis as described in methods. Values graphed are the
mean + SE of three replicates for each sample.
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Figure 9: Effect of sample preparation on plasma pterins from healthy volunteers.
Plasma neopterin (A) and total neopterin (B) concentrations for five apparently healthy
volunteers. Samples were prepared for analysis using either acetonitrile (■) or TCA (□)
for protein precipitation before HPLC analysis as described in methods. Values graphed
are the mean + SE of three replicates for each sample.
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Figure 10: Comparison of average plasma pterin concentrations from different
sample preparations.
Mean plasma total neopterin, neopterin and 78NP concentrations for the two
experimental groups (septicaemia and healthy controls). The 78NP concentration for
each sample was calculated by subtracting the total neopterin concentration from the
plasma neopterin concentration. The figure shows the mean of the acetonitrile (■) and
TCA (□) treated samples from Figure 8 and Figure 9.
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Oxidation and Inflammation in Atherosclerotic Plaques
Patient Information
A total of eight patients participated in this study. Participants had an average age
of 73 years and were either ex- or non-smokers. None of the patients were diabetic and
all patients were taking aspirin for their condition. Plaques removed all showed a high
degree of stenosis, ranging from 65 to 90 percent, as this is a prerequisite of the surgery.
Patients suffered from various symptoms including hypertension, transient ischemic
attacks (TIA), stroke, and amaurosis fugax (temporary loss of vision). Patients suffering
from hypertension were receiving medications for this symptom (one or a combination of
the following: lorsatan, frusemide, inhibace, cilazapril, bendofluazide and candesartan).
Other medications prescribed varied from patient to patient and were classified as either
statins or beta blockers. Statins prescribed to one or more patients were atorvastatin and
simvastatin. The prescribed beta blocker was metaprolol. Medications not related to their
condition are not included in the patient summary. Data for the individual patients is
summarised in Table 1. Classification of plaques was based on qualitative observation by
Table 1: Characteristics of carotid endarterectomy patients and plaques.
Symptoms: Medication:
Patient/
Plaque Sex
Age
(years)
Plaque
classifica-
tion
Stenosis
%
H
yper-
tension
TIA
Stroke
A
m
aurosis
fugax
Statin
B
eta
blocker
A F 76 neither 80  
B F 71 thrombosed 90    
C M 71 calcified 70   
D F 64 thrombosed 75    
E F 72 calcified 90   
F M 67 thrombosed 80   
G M 80 neither 80   
H M 83 calcified 65    
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the researcher and was placed into one of three categories: thrombosed, heavily calcified,
or neither. This classification along with the percent of stenosis for each plaque is also
given in Table 1.
Compiled Plaque Data
Six plaques (A-F) were analysed and data for two further plaques (G – DB011203
& H – AC100903) were taken from previous analyses performed by Carole Firth (Firth
2006)
Markers of protein oxidation which includes DOPA, dityrosine and carbonyls
have been expressed per gram of protein, as this is of greater consequence as a limiting
factor compared with plaque mass as a whole and removes the variable of protein
concentration which may mask or exaggerate the actual concentrations in the different
sections. This idea was also applied to TBARS as a measure of lipid oxidation and the
lipid soluble vitamin E, thus they were presented as per gram of cholesterol. Raw data
presented per gram of plaque is attached in appendix I.
Table 2: Data averages for individual plaques
Plaque
Total
Mass
(g)
Protein
(mg/g
plaque)
Cholesterol
(µmole/g
plaque)
Carbonyls
(µmole/g
protein)
Dityrosine
(nmole/g
protein)
DOPA
(nmole/g
protein)
Neopterin*
(nmole/g
plaque)
TBARS
(nmole/
mole
cholesterol)
Vitamin E
(µmole/
mole
cholesterol)
A 1.50 70.3 75.8 4.79 9.35 245.18 0.087* 115.08 512.2
B 0.76 92.0 80.9 5.00 149.26 340.54 0.211* 86.41 1030.8
C 1.31 64.3 58.0 4.43 14.14 79.08 1.588 77.34 1594.5
D 0.82 92.1 47.4 4.82 101.76 179.90 1.795 178.08 3073.4
E 0.51 94.8 25.8 3.02 0.00 84.59 1.262 607.54 1640.8
F 0.38 140.3 59.3 2.76 66.85 72.05 0.921 255.53 2737.0
G 0.90 77.6 37.2 2.23 5.84 170.77 0.207* 128.1 582.6
H 2.86 67.1 92.4 5.62 68.37 182.04 0.158* 48.57 458.6
* Neopterin in plaques A, B, G and H were measured using the TCA protein precipitation method;
plaques C, D, E and F were measured using the acetonitrile protein precipitation method.
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Plaque A – IH120704
Approximately 37 mm of plaque material was removed from the right internal
carotid artery of patient A (Figure 11). It was dissected into eight segments of 3-6 mm
each. The plaque showed neither a high degree of calcification nor evidence of
thrombosis so was classified as neither. For purposes of between plaque comparisons,
section 1 was assigned as pre-bifurcation, 2-4 as bifurcation and sections 5-8 as post-
bifurcation.
Figure 11: Plaque A - Cross sections of the atheromatous material removed from
the carotid artery of patient A.
The plaque was separated and removed from the right internal carotid artery of patient A.
It was dissected into eight segments labelled sections 1-8 as shown. Section 1 was
assigned as pre-bifurcation, sections 2-4 as bifurcation and sections 5-8 as post-
bifurcation.
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Protein and Cholesterol
Cholesterol content of plaque A shows higher levels of cholesterol (p<0.05) to be
present in the bifurcation and just down stream of the bifurcation in sections 2 to 5
(Figure 12B).
Due to a shortage of homogenate material protein for plaque A was only able to
be measured in duplicate; consequently any differences in the protein concentration can
not be described as statistically significant. However observation of the data (Figure
12A) does show a trend of higher protein levels in earlier sections of the plaque which
tends to decrease as we precede downstream of the bifurcation.
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Figure 12: Protein and cholesterol concentrations in eight sections of plaque A.
Protein content (A) was analysed in individual sections using a BCA protein
determination kit. Cholesterol content (B) was determined in each section by
spectrophotometer. Values shown represent the mean + SE of triplicates for cholesterol
and duplicates for protein.
Neopterin
Neopterin levels in plaque A were measured using the TCA protein precipitation
method. The average neopterin concentration across all sections of the plaque was 0.087
nmoles/g of plaque. The individual sections show a significant peak (p < 0.05) in the
first, pre-bifurcation section and a significant trough in the final section, with the
remaining sections’ neopterin concentration falling in between these levels (Figure 13).
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Figure 13: Neopterin concentration in
eight sections of plaque A.
Individual sections of plaque A were
treated with TCA to precipitate proteins
prior to HPLC analysis for neopterin.
Values shown represent the mean + SE
of triplicates.
Figure 14: Vitamin E concentration in
eight sections of plaque A.
Individual sections of plaque A were
analysed using HPLC for their vitamin E
content. Values shown represent the
mean + SE of triplicates.
Vitamin E
A significant peak in vitamin E is present in section 4 of plaque A and section 7
represents a significant trough (Figure 14). The plaque did not, however, show any
apparent trend in the localisation of vitamin E.
Markers of Oxidation
DOPA maintained a consistent concentration of approximately 200 nmoles/g of
protein in the first six sections of plaque A, after which it increased significantly
(p<0.05), to almost twice that value in the tail sections (Figure 15A).
In contrast to DOPA, the later sections, 7 and 8, contained no detectable
dityrosine; the majority of dityrosine being present in the pre- and bifurcation sections,
with a peak of 21.9 ±1.1 nmoles/g of protein in section 3 (Figure 15B).
Carbonyls did not reveal any obvious trends and, apart from section 4, there was
no significant difference between any of the sections (p<0.05); section 4 representing a
peak of 8.72 ± 0.17 µmoles/g of protein for plaque A (Figure 15C).
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TBARS showed a slight trend of higher concentrations in the later, post-
bifurcation sections with sections 6 and 7 representing a significant peak (p<0.05)
(Figure 15D).
1 2 3 4 5 6 7 8
0
100
200
300
400
500
Plaque section
D
O
PA
(n
m
ol
es
/g
pr
ot
ei
n)
1 2 3 4 5 6 7 8
0
5
10
15
20
25
Plaque section
D
ity
ro
si
ne
(n
m
ol
es
/g
pr
ot
ei
n)
1 2 3 4 5 6 7 8
0.0
2.5
5.0
7.5
10.0
Plaque section
C
ar
bo
ny
ls
(u
m
ol
es
/g
pr
ot
ei
n)
1 2 3 4 5 6 7 8
0
100
200
300
Plaque section
TB
A
R
S
(u
m
ol
es
/m
ol
e
ch
ol
es
te
ro
l)
A B
C D
Figure 15: Markers of oxidation in eight sections of plaque A.
Individual sections of plaque A were analysed for DOPA (A), dityrosine (B), carbonyl
(C) and TBARS (D) content. Values shown represent the mean + SE of triplicates.
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Plaque B – HW290304
Approximately 25 mm of plaque material was removed from the left carotid
artery of patient B (Figure 16). It was dissected into seven segments ranging from 0.08-
0.13 g in weight. The plaque showed evidence of a major thrombic event, with section 7
consisting entirely of a blood clot, and thus was placed in the thrombosis classification.
For purposes of between plaque comparisons, sections 1 and 2 were assigned as pre-
bifurcation, 3-5 as bifurcation and section 6 as post-bifurcation. As section 7 did not
contain any actual plaque material, it was not included in the between plaque analyses;
however, the data was included in the individual plaque data.
Figure 16: Plaque B - Cross sections of the atheromatous material removed from
the carotid artery of patient B.
The plaque was separated and removed from the left carotid artery of patient B. It was
dissected into seven segments labelled sections 1-7 as shown. Sections 1-2 were assigned
as pre-bifurcation, sections 3-5 as bifurcation and section 6 as post-bifurcation. Section 7
was a blood clot and for purposes of between-plaque analysis was not included in the
data set however the data is shown for the individual plaque.
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Protein and Cholesterol
Protein concentration per gram of plaque was similar across the majority of the
plaque sections apart from a significant (p<0.01) spike in section 6, at the tail end of the
plaque B (Figure 17A).
Cholesterol content in the leading edge of plaque B is significantly (p<0.01)
lower then subsequent sections, with a value of just 25.5 ± 5.4 µmoles/g of plaque, it is
less then half that of any other section (Figure 17B). Cholesterol levels in the blood clot
(section 7) are higher; and overall the blood clot shows a higher cholesterol to protein
ratio then the plaque tissue.
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Figure 17: Protein and cholesterol concentrations in seven sections of plaque B.
Protein content (A) was analysed in individual sections using a BCA protein
determination kit. Cholesterol content (B) was determined in each section by
spectrophotometer. Values shown represent the mean + SE of triplicates.
Neopterin
Neopterin levels in plaque B were measured using the TCA protein precipitation
method. The concentration of neopterin in the pre-bifurcation zone and the distal end of
the plaque are considerably higher (p<0.001) then the areas of, and directly after, the
bifurcation (Figure 18). The average neopterin concentration of 0.211 nmoles/g of plaque
is more then doubled in the peak concentration of section 2.
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Figure 18: Neopterin concentration in
seven sections of plaque B.
Individual sections of plaque B were
treated with TCA to precipitate proteins
prior to HPLC analysis for neopterin.
Values shown represent the mean + SE
of triplicates.
Figure 19: Vitamin E concentration
for seven sections of plaque B.
Individual sections of plaque B were
analysed for their vitamin E content by
HPLC. Values shown represent the
mean + SE of triplicates.
Vitamin E
A trend of decreasing vitamin E concentration is apparent as we move from the
proximal end of plaque B downstream (Figure 19). The pre-bifurcation sections (1 and 2)
are significantly higher (p<0.05) then section 3, 5 and 6. The blood clot at section seven
has a considerably (p<0.05) lower concentration of vitamin E in relation to all the
sections containing plaque tissue.
Markers of oxidation
DOPA concentration is greatest at the proximal end at a concentration of 606 ±
120 nmoles/g of protein, the majority of the later sections being significantly lower then
this value (p<0.05), with a trend of lower levels in the post-bifurcation section (Figure
20A).
Dityrosine, on the other hand, is at its lowest concentration for plaque B in
section 1 (Figure 20B). Instead reaching a significant (p<0.05) peak at the bifurcation in
section 4, before dropping again in the post bifurcation sections.
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The variation in the data for carbonyls means that no significant trends can be
postulated from this data (Figure 20C). TBARS had a similar problem with large
variation in replicates, however, when data was pooled into zones (bifurcation, pre-
bifurcation, etc) the bifurcation sections were shown to be significantly higher (p<0.01)
then the pre- and post-bifurcation sections (Figure 20D).
Section 7, the blood clot, shows medium to high levels of all the oxidative
markers compared to other sections (Figure 20). Most notably, the value of 625 ± 24
nmoles of dityrosine/g of protein (Figure 20B), for exceeds the values obtained in plaque
tissue for this, or any other, plaque.
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Figure 20: Markers of oxidation in seven sections of plaque B.
Individual sections of plaque B were analysed for their content of: DOPA (A), dityrosine
(B), carbonyl (C) and TBARS (D). Values shown represent the mean + SE of triplicates.
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Plaque C – WC210604
Approximately 31 mm of plaque material was removed from the left carotid
artery of patient C (Figure 21). It was dissected into seven segments ranging from 0.11-
0.27 g in weight. The plaque was classified as highly calcified, as it was very solid and
crunchy during dissection and homogenisation, particularly sections 2 and 4. For
purposes of between plaque comparisons, sections 1 and 2 were assigned as pre-
bifurcation, 3-5 as bifurcation and sections 6 and 7 as post-bifurcation.
Figure 21: Plaque C - Cross sections of the atheromatous material removed from
the carotid artery of patient C.
The plaque was separated and removed from the left carotid artery of patient C. It was
dissected into seven segments labelled sections 1-7 as shown. Sections 1-2 were assigned
as pre-bifurcation, sections 3-5 as bifurcation and sections 6-7 as post-bifurcation.
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Protein and cholesterol
Protein concentration per gram of plaque is reasonably consistent throughout the
entire plaque, with section 3 representing a significant (p<0.05) peak at 78.5 ± 5.7
nmoles/g of plaque (Figure 22A).
Cholesterol content in the leading edge of plaque C is significantly lower
(p<0.001) then the later of the plaque (Figure 22B). Sections 3 and 5, localised in the
bifurcation, represent significant peaks (p<0.001) in cholesterol concentration.
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Figure 22: Protein and cholesterol concentrations in seven sections of plaque C.
Protein content (A) was analysed in individual sections using a BCA protein
determination kit. Cholesterol content (B) was determined in each section by
spectrophotometer. Values shown represent the mean + SE of triplicates.
Neopterin
Neopterin levels in plaque C were measured using the ACN protein precipitation
method. Neopterin within plaque C did not demonstrate any real pattern in regard to
localisation of the sections, with significantly high and low neopterin concentrations in
each of the pre-, post- and bifurcation zones (p<0.001) (Figure 23).
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Figure 23: Neopterin concentration in
seven sections of plaque C.
Individual sections of plaque C were
treated with ACN to precipitate proteins
prior to HPLC analysis for neopterin.
Values shown represent the mean + SE
of triplicates.
Figure 24: Vitamin E concentration in
seven sections of plaque C.
Individual sections of plaque C were
analysed using HPLC for their vitamin E
content. Values shown represent the
mean + SE of triplicates.
Vitamin E
Vitamin E showed significantly low (p<0.001) concentrations per gram of
cholesterol in sections 3 and 6 representing the secondary branch of the bifurcation along
with section 5 (Figure 24). Higher values are found pre-bifurcation in sections 1 and 2,
and in the distal section of the primary branch (section 7).
Markers of oxidation
The peak in DOPA of 181 ± 27 nmoles/g of protein in section 2 of the pre-
bifurcation zone represents the only significant (p<0.05) variation in DOPA
concentration for plaque C (Figure 25A).
Dityrosine shows a trend of low concentrations in the proximal and distal ends of
the plaque C with significant (p<0.05) increases in dityrosine content as we move
inwards towards the bifurcation of the plaque, peaking at 32 ± 2 nmoles/g of protein in
section 4 (Figure 25B).
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As with DOPA, the only significant (p<0.05) variation in carbonyls concentration
is in the pre-bifurcation zone of the plaque, with a peak in section 1 of 7.4 ± 0.7 µmoles/g
of protein (Figure 25C).
Plaque C shows very high levels (p<0.01) of TBARS in both section 4 of the
bifurcation and in the distal end of the primary branch (section 7) (Figure 25D). In
contrast the sections representing the secondary branch (sections 3 and 6) show
significantly (p<0.05) low concentrations, as do the sections upstream of the bifurcation.
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Figure 25: Markers of oxidation in seven sections of plaque C.
Individual sections of plaque C were analysed for their content of: DOPA (A), dityrosine
(B), carbonyl (C) and TBARS (D). Values shown represent the mean + SE of triplicates.
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Plaque D – MS200405
Approximately 27 mm of plaque material was removed from the common carotid
artery of patient D (Figure 26). It was dissected into six segments ranging from 0.06-
0.27g in weight. The plaque was classified as thrombosed as blood clotting was evident
throughout the plaque, especially in section 3, 4 and 5. For purposes of between plaque
comparisons, sections 1 and 2 were assigned as pre-bifurcation, 3 and 4 as bifurcation
and sections 5 and 6 as post-bifurcation.
Figure 26: Plaque D - Cross sections of the atheromatous material removed from
the carotid artery of patient D.
The plaque was separated and removed from the common carotid artery (side not stated)
of patient D. It was dissected into six segments labelled sections 1-6 as shown. Sections
1-2 were assigned as pre-bifurcation, sections 3-4 as bifurcation and sections 5-6 as post-
bifurcation. Note the camera normally used for photography was not available at time of
dissection, thus the lower quality image.
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Protein and cholesterol
Protein content in plaque D is significantly lower (p<0.05) within sections 2 and
4, and peaks within section 3 (Figure 27A). The protein concentration fluctuates within
the pre- and bifurcation zones, thus no trend in protein concentration is apparent.
The post-bifurcation region of plaque D shows significantly (p<0.05) higher
cholesterol content in plaque D then that seen upstream of and within bifurcation
sections.
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Figure 27: Protein and cholesterol concentrations in six sections of plaque D.
Protein content (A) was analysed in individual sections using a BCA protein
determination kit. Cholesterol content (B) was determined in each section by
spectrophotometer. Values shown represent the mean + SE of triplicates.
Neopterin
Neopterin levels in plaque D were measured using the ACN protein precipitation
method. The proximal end of the plaque showed a significantly greater (p<0.001) level of
neopterin then that present in the rest of the plaque with a concentration of 2.98 ± 0.09
nmoles/g of plaque, almost double that seen in other sections (Figure 28). Section 4
represents a significant trough (p<0.001) at the bifurcation zone.
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Figure 28: Neopterin concentration in
six sections of plaque D.
Individual sections of plaque D were
treated with ACN to precipitate proteins
prior to HPLC analysis for neopterin.
Values shown represent the mean + SE
of triplicates.
Figure 29: Vitamin E for six sections
of plaque D.
Individual sections of plaque D were
analysed using HPLC for their vitamin E
content. Values shown represent the
mean + SE of triplicates.
Vitamin E
Sections 1 and 5 represent significant peaks (p<0.01) in vitamin E localised
within the pre-bifurcation and post-bifurcation zones respectively (Figure 29). The
remaining sections of plaque D have similar vitamin E concentrations of approximately
2.5 mmoles/mole of cholesterol.
Markers of oxidation
Large variation in some of the replicates for DOPA prevent much of the
differences between sections from being significant, however the two sections with the
lowest DOPA content, 1 and 5, are significantly different from section 2 (p<0.05), and a
general trend of lower levels of DOPA are found in the post-bifurcation zone (Figure
30A).
There were no detectable levels of dityrosine in section 1 of plaque D, however
this was followed by a large increase in concentration in section 2, similar to that
51
observed in the DOPA samples (Figure 30B). Dityrosine peaks significantly (p<0.05) in
section 4 at 213 ± 6 nmoles/g of protein, and then drops again drastically section 6.
The average carbonyl content for plaque D is 4.8 µmoles/g of protein and there is
no significant variation between the any of the sections due to the large variation between
replicates (Figure 30C).
TBARS shows a general trend of significantly higher levels (p<0.05) at the
proximal end of plaque D decreasing to almost nothing at the distal end (Figure 30D).
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Figure 30: Markers of oxidation in six sections of plaque D.
Individual sections of plaque D were analysed for their content of: DOPA (A), dityrosine
(B), carbonyl (C) and TBARS (D). Values shown represent the mean + SE of triplicates.
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Plaque E – ES020407
Approximately 18 mm of plaque material was removed from the left common
carotid artery of patient E (Figure 31). It was dissected into six segments ranging from
0.03-0.18 g in weight. The plaque was classified as heavily calcified as it was very solid
and crunchy during dissection and homogenisation, especially in sections 2, 3, and 5. For
purposes of between plaque comparisons, sections 1 and 2 were assigned as pre-
bifurcation, 3-5 as bifurcation and section 6 as post-bifurcation.
Figure 31: Plaque E - Cross sections of the atheromatous material removed from
the carotid artery of patient E.
The plaque was separated and removed from the left common carotid artery of patient E.
It was dissected into six segments labelled sections 1-6 as shown. Sections 1-2 were
assigned as pre-bifurcation, section 3-5 as bifurcation and section 6 as post-bifurcation.
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Protein and cholesterol
The marginal sections (1, 4 and 6) of plaque E show considerably higher
concentrations (p<0.05) of protein per gram of plaque then those making up the body of
the plaque (Figure 32A). This will be due, in part, to the large content of calcified gruel
observed in sections 2, 3 and 5 contributing to the mass of these sections.
Cholesterol in section 2 is significantly higher (p<0.01) then in all other sections
of plaque E (Figure 32B). The remaining sections are all within a similar range with
section 4 representing a peak and 3 a trough within these sections (p<0.05). No trend
related to localisation of the sections or observed calcium content is readily apparent for
cholesterol in this plaque.
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Figure 32: Protein and cholesterol concentrations in six sections of plaque E.
Protein content (A) was analysed in individual sections using a BCA protein
determination kit. Cholesterol content (B) was determined in each section by
spectrophotometer. Values shown represent the mean + SE of triplicates.
Neopterin
Neopterin in plaque E was measured using the acetonitrile protein precipitation
method. A pattern of neopterin content (Figure 33) almost identical to that observed for
protein localization is evident. Again the sections at the margins of the plaque contain
significantly greater concentrations (p<0.001) of neopterin then those in the core With a
higher level also measured in the distal sction at the start of the external carotid artery.
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Figure 33: Neopterin concentration in
six sections of plaque E.
Individual sections of plaque E were
treated with ACN to precipitate proteins
prior to HPLC analysis for neopterin.
Values shown represent the mean + SE
of triplicates.
Figure 34: Vitamin E concentration in
six sections of plaque E.
Individual sections of plaque D were
analysed for their vitamin E content
using HPLC. Values shown represent
the mean + SE of triplicates.
Vitamin E
The first bifurcation section, 3, contains significantly higher (p<0.05) levels of
vitamin E compared to the secondary branch (section 4) (Figure 34). Otherwise there is
no significant variation across the length of the plaque, and no pattern is apparent either
in regards to localisation or the observed calcium content of the sections.
Markers of oxidation
The average DOPA content of plaque E is 84 ± 16 nmoles per gram of protein
(Figure 35A). Carbonyl concentration across the entire plaque averaged to 3.0 ± 0.5
µmoles per gram of protein (Figure 35B). Due to large variation within the section’s
replicates neither DOPA nor carbonyl content of plaque E showed any significant
variation between the sections.
The leading edge of plaque E shows significantly greater TBARS content
(p<0.05) then that in the immediately adjacent section and the distal ends of both
branches (Figure 35C). Similar levels to those in section 1 are also present in the gruelly
sections of the bifurcation (sections 3 and 5).
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Dityrosine was not present in any of the sections of plaque E within the detection
limits of the assay (data not shown).
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Figure 35: Markers of oxidation in six sections of plaque E.
Individual sections of plaque E were analysed for their content of: DOPA (A), carbonyl
(B) and TBARS (C). Values shown represent the mean + SE of triplicates.
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Plaque F – GP050407
Approximately 32 mm of plaque material was removed from the left common
carotid artery of patient F (Figure 36). It was dissected into six segments ranging from
0.04-0.11 g in weight. The plaque was classified as thrombosed as blood clotting was
evident throughout the plaque especially in sections 5 and 6. For purposes of between
plaque comparisons, sections 1 and 2 were assigned as pre-bifurcation, 3-5 as bifurcation
and section 6 as post-bifurcation.
Figure 36: Plaque F - Cross sections of the atheromatous material removed from
the carotid artery of patient F.
The plaque was separated and removed from the left common carotid artery of patient F.
It was dissected into six segments labelled sections 1-6 as shown. Sections 1-2 were
assigned as pre-bifurcation, section 3-5 as bifurcation and section 6 as post-bifurcation.
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Protein and cholesterol
Protein concentration of plaque F peaks in the distal sections of the primary
branch around and after the bifurcation (p<0.05) (Figure 37A). The preceding sections
show no significant variations.
The leading edge and distal section of the secondary branch have significantly
lower (p<0.01) cholesterol contents compared with the other sections, which show
almost twice as much cholesterol per gram of plaque (Figure 37B).
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Figure 37: Protein and cholesterol concentrations in six sections of plaque F.
Protein content (A) was analysed in individual sections using a BCA protein
determination kit. Cholesterol content (B) was determined in each section by
spectrophotometer. Values shown represent the mean + SE of triplicates.
Neopterin
Neopterin for plaque F was measured using the acetonitrile protein precipitation
method. The pre-bifurcation sections and the secondary branch contain lower neopterin
concentrations with the lowest concentration occurring in the leading edge (Figure 38).
Neopterin concentration is highest in section 4 then drops moving down the primary
branch though not dropping as low as levels in the earlier sections (p<0.05).
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Figure 38: Neopterin concentration in
six sections of plaque F.
Individual sections of plaque F were
treated with ACN to precipitate proteins
prior to HPLC analysis for neopterin.
Values shown represent the mean + SE
of triplicates.
Figure 39: Vitamin E in six sections of
plaque F.
Individual sections of plaque E were
analysed for their vitamin E content
using HPLC. Values shown represent
the mean + SE of triplicates.
Vitamin E
Vitamin E shows the lowest concentration per mole of cholesterol in the distal
end of the primary branch (p<0.05) (Figure 39). The peaks in sections 1 and 3 correspond
to areas of low cholesterol levels; however they are not significantly different from
sections 2 and 4 which border them.
Markers of oxidation
The average concentration of DOPA across plaque F was 72 ± 5 nmoles per gram
of protein (Figure 40A). Dityrosine gave an average of 67 ± 7 nmoles per gram of protein
(Figure 40B). No significant variation between sections is shown by either of the
oxidative markers.
The majority of sections in plaque F showed no significant variation in carbonyl
content; section 5 being the exception with a significantly greater (p<0.05) concentration
of carbonyls per gram of protein (Figure 40C).
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Significant differences in TBARS content cannot be attributed between the
sections of plaque F apart from sections 3 and 4 which represent lowest and highest
(p<0,05) TBARS concentration per gram of cholesterol respectively (Figure 40D).
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Figure 40: Markers of oxidation for six sections of plaque F.
Individual sections of plaque F were analysed for their content of: DOPA (A), dityrosine
(B), carbonyl (C) and TBARS (D). Values shown represent the mean + SE of triplicates.
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Correlations between markers of oxidation and inflammation for
individual and combined plaques
Both the combined plaque data and the individual plaque data was assessed for
correlations. Significant relationships are outlined in table 3. Data was expressed per
gram of plaque for the analysis.
Relationships for neopterin were assessed in two separate groups depending on
the method used for protein precipitation prior to measurement (TCA or Acetonitrile).
This is due to the profound difference in neopterin levels produced by this factor that
may mask any relationships between other markers. The method involved in the
relationship is marked in brackets, with the abbreviation ACN used for acetonitrile.
Of the significant correlations seen in the combined data set, only five were found
to also be significant in an individual plaque: dityrosine vs. cholesterol and carbonyl vs.
vitamin E in plaque B; carbonyls vs. protein and neopterin (ACN) vs. carbonyls in plaque
E; and TBARS vs. vitamin E in plaque C.
Only two correlations were present in more then one plaque: vitamin E vs.
cholesterol was significant in plaques A and E; and neopterin (ACN) vs. protein was
significant in plaques C and E. Despite these relationships appearing in two plaques; the
relationship did not hold in the combined plaque data.
Plaque D was the only plaque to demonstrate any significant negative correlations
(Table 3) and only one negative correlation appears in the combined plaque data, DOPA
vs. vitamin E, which does not correspond with the associations found in plaque D.
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Table 3: Correlations between markers of oxidation and inflammation in sectioned
plaques.
Plaque sections were analysed for the content of protein, cholesterol, neopterin, vitamin
E, DOPA, dityrosine, carbonyls and TBARS. Relationships between these parameters
were assessed for the combined data set and for the individual plaques. Data was
expressed per gram of plaque for the analysis. Significant associations are listed and the
level of significance is indicated by * for p<0.05; ** for p<0.01; or *** for p<0.001.
Relationships found in individual plaques that correspond to combined plaque data are
noted in brackets beside the combined plaque correlation. Relationships present in more
then one plaque are marked with †. Plaque classifications are given beside the plaque.
Correlation r (Pearson) p value N
Combined Plaque Data
DOPA vs. Vitamin E -0.292 0.033 (*) 53
DOPA vs. Dityrosine 0.330 0.016 (*) 53
Dityrosine vs. Cholesterol (B) 0.477 0.000 (***) 53
Carbonyl vs. Protein (E) 0.346 0.011 (*) 53
Carbonyl vs. Vitamin E (B) 0.430 0.001 (**) 53
TBARS vs. Protein 0.485 0.000 (***) 53
TBARS vs. Vitamin E (C) 0.286 0.038 (*) 53
Vitamin E vs. Protein 0.356 0.008 (**) 53
Neopterin (ACN) vs. Carbonyl (E) 0.465 0.019 (*) 25
Plaque A - Neither
Dityrosine vs. Protein 0.801 0.017 (*) 8
Vitamin E vs. Cholesterol † 0.970 0.000 (***) 8
Plaque B - Thrombosed
Dityrosine vs. Cholesterol 0.766 0.044 (*) 7
Carbonyl vs. Vitamin E 0.790 0.034 (*) 7
Plaque C - Calcified
Neopterin (ACN) vs. Protein † 0.853 0.015 (*) 7
Vitamin E vs. TBARS 0.784 0.037 (*) 7
Plaque D - Thrombosed
Protein vs. Cholesterol -0.866 0.026 (*) 6
Neopterin (ACN) vs. Dityrosine -0.822 0.045 (*) 6
Carbonyls vs. Cholesterol -0.823 0.044 (*) 6
Carbonyls vs. TBARS 0.851 0.032 (*) 6
Plaque E - Calcified
Neopterin (ACN) vs. Protein † 0.971 0.001 (**) 6
Neopterin (ACN) vs. Carbonyls 0.866 0.026 (*) 6
Carbonyls vs. Protein 0.881 0.021 (*) 6
Vitamin E vs. Cholesterol † 0.932 0.007 (**) 6
Plaque F - Thrombosed
DOPA vs. Cholesterol 0.825 0.043 (*) 6
TBARS vs. Cholesterol 0.855 0.030 (*) 6
TBARS vs. Neopterin (ACN) 0.827 0.042 (*) 6
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Analysis of Variance for markers of oxidation and inflammation for
combined plaque data
Factorial ANOVA was performed on the pooled plaque data to establish the
effects of localisation zone within the plaque (pre-, post- or bifurcation) and classification
of the plaque (heavily calcified or thrombosed) on markers of oxidation and
inflammation. In the case of neopterin method of measurement (Acetonitrile or TCA)
was also assessed.
As with the individual plaque data; DOPA, dityrosine and carbonyls were
analysed per gram of protein and vitamin E and TBARS per gram of cholesterol. Prior to
ANOVA samples were assessed for homogeneity of variances and normality; if data did
not fit these assumptions it was transformed accordingly (logarithmic transformation).
Only variables that showed significant effects are given.
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Variance due to localisation in pre-, post- and bifurcation zones
Cholesterol showed lower concentrations in the pre-bifurcation zone then those in
the bifurcation and post-bifurcation zones (p<0.001) (Figure 41A). Levels of dityrosine
in plaques were lower in the pre-bifurcation zone then in the bifurcation zone (p<0.05)
(Figure 41B). TBARS concentrations were higher in the bifurcation zone of plaques then
in the post-bifurcation zone (p<0.001) (Figure 41C). Neopterin concentrations were
lowest in the bifurcation zone of plaques (p<0.05) (Figure 41D).
Variance due to classification as containing thrombosis, heavily calcified or neither
Plaques classified as containing thrombosis showed higher protein content then
both the heavily calcified plaque and plaques classified as neither (p<0.001) (Figure
42A). Cholesterol concentration of thrombosed plaques was higher then theneither thrombosed h. calcified
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concentration found in heavily calcified plaques (p<0.05) (Figure 42B). DOPA content is
lower in both the thrombosed (p<0.05) and heavily calcified (p<0.001) plaques then in
the plaques classified as neither (Figure 42C). Plaques with evidence of thrombosis
showed higher levels of dityrosine then both the heavily calcified plaques and those
plaques that were neither thrombosed or calcified heavily (p<0.001) (Figure 42D).
Vitamin E content differed between each of the plaque groups with thrombosed plaques
showing the greatest amount (p<0.001), followed by heavily calcified plaques and
plaques classified as neither showing the least (p<0.001) (Figure 42E).
Variance due to interactions between zone and classification
Along with a significant variation due to zone and classification individually
cholesterol also showed a significant interaction between the two factors (p<0.001) with
plaques classified as neither thrombosed nor heavily calcified showing a spike in
cholesterol in the bifurcation zone in relation to pre- and post- zones and the other
classifications (Figure 43A).
Carbonyls, which failed to show significant variation with the individual factors,
did show a significant interaction between zone and classification (p<0.01). The plaques
classified as neither thrombosed nor heavily calcified deviated from the general trend by
showing lower carbonyl concentrations in the pre bifurcation zone then in the post- and
bifurcation zones and in relation to the other classifications (Figure 43B).
While the single factor ANOVA demonstrated the thrombosed plaques to be
lower in DOPA content then plaques in the ‘neither’ classification, multi-factor ANOVA
demonstrates that in fact the thrombosed plaques only have significantly lower DOPA
content in the post-bifurcation zone and not across the entire plaque (p<0.05) (Figure
43C).
ANOVA of dityrosine for classification alone showed thrombosed plaques to be
significantly higher in dityrosine then the other plaques; however, inclusion of zone
introduces a significant interaction (p<0.001). The interaction factor shows that
thrombosed plaques have significantly higher dityrosine then ‘neither’ plaques in the
post-bifurcation zone only. Conversely, heavily calcified plaques have significantly
lower dityrosine then thrombosed plaques in the pre- and bifurcation zones but similar
levels in the post-bifurcation zone.
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Figure 43: Variance in oxidative markers due to interactions between plaque
classification and zone.
Factorial ANOVA results for cholesterol (A), carbonyls (B), DOPA (C), and dityrosine
(D); LS mean for zone (pre-, post- and bifurcation) vs. classification (thrombosed ,
heavily calcified , and neither ). Vertical bars denote 0.95 confidence intervals.
Variance in neopterin concentration of plaques due to the method of measurement
The method of protein precipitation prior to neopterin measurement produces a
significant difference in the value of neopterin obtained (p<0.001). As observed with
plasma samples in the neopterin analysis development, measurement of plaque samples
with acetonitrile as the precipitation reagent demonstrated higher values of neopterin then
that produced with a TCA precipitant (Figure 44A).
A significant interaction factor between method of measurement and zone was
demonstrated (p<0.001). It showed the pre-bifurcation zone to have higher neopterin
levels then the corresponding bifurcation and post-bifurcation zones, but only when
measured with the TCA precipitation method, as this trend was not present in plaques
measured by acetonitrile precipitation (Figure 44B).
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Figure 44: Variance in neopterin due to method of measurement.
ANOVA results for neopterin: (A) LS mean by method of measurement (TCA and
Acetonitrile) and (B) LS mean by method of measurement (TCA and Acetonitrile )
vs. zone (pre-, post- and bifurcation). Vertical bars denote 0.95 confidence intervals.
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Discussion
Neopterin Analysis Development
Initial research was focused on improving detection of neopterin and 7,8-
dihydroneopterin (78NP) in plasma. Previous analysis of neopterin in the laboratory had
been performed with trichloroacetic acid (TCA) as the protein precipitation reagent prior
to HPLC. However; acidic conditions have been previously reported to cause significant
oxidation of 78NP to neopterin (Werner et al. 1987). With TCA we observed up to 60%
of 78NP being oxidised to neopterin (Figure 6). Similar problems were also encountered
using perchloric acid. The effect of this oxidation would not be apparent when dealing
with neopterin samples alone, but would cause a substantial underestimate of 78NP
concentrations and a slight additional overestimate of neopterin when working with
biological samples. Ascorbate was found to reduce this oxidation but was not completely
effective (Figure 6). This effect of ascorbate has been described previously (Werner et al.
1987). Therefore acetonitrile was examined as an alternative to acid precipitation of
proteins. We found that 78NP was not oxidised by treatment with acetonitrile making it a
more suitable reagent for protein precipitation.
The use of acetonitrile, as the protein precipitating reagent in plasma prior to
HPLC measurement of neopterin gave several additional advantages over TCA.
Acetonitrile not only improved the resolution of peaks and the signal to noise ratio in
HPLC chromatograms (Figure 7) but also gave considerably higher neopterin
concentrations (Figure 10). This increase in neopterin concentration with acetonitrile was
also apparent in measurement of plaque samples where a significant difference in
neopterin concentration was seen between the acetonitrile and TCA treated groups
(Figure 44).
The variation between the acetonitrile and TCA treated plasma samples in
neopterin and total neopterin levels can not be fully explained by the acid-induced
oxidation of 78NP to neopterin. If this was the case only total neopterin concentrations
would be expected to increase; instead the levels of both total neopterin and neopterin
increased dramatically with the acetonitrile treatment. This increase in neopterin with
acetonitrile treatment was not observed using protein free buffers which suggests the
effect is due to the actual precipitation of protein. The most plausible explanation being
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that in addition to the acid oxidation, a varying level of pterin is co-precipitating with the
serum proteins and is lost from the sample when treated with TCA.
TCA treatment shows a picture of healthy subjects having the majority of the
pterin as 78NP (75%) (Figure 10) which is close to the published 2:1 ratio (Wachter et al.
1992). In the septicemia patients, this ratio is reversed where the majority of the pterin is
neopterin (83%). This does agree with the hypothesis that 78NP can be oxidised to
neopterin by oxidants produced during inflammation. However, the TCA data does not
show a significant overall increase in total pterin when comparing the healthy controls
and the septicemia patients (Figure 10). This is not consistent with what is known about
pterin release from macrophages during the immune response (Huber et al. 1984,
Wachter et al. 1989). The acetonitrile data shows the overall level of pterins in the
plasma increasing 203% with the level of 78NP increasing from 19% to 28% which
would be consistent with increased production of 78NP by macrophage cells. This is
especially relevant if one of the roles of 78NP is to provide protection to cells and
biomolecules(Gieseg et al. 1995, Gieseg et al. 2001b, Mori et al. 1996). The overall
increase in neopterin/78NP is also consistent with the hypothesis that neopterin increases
the potency of various cytotoxic agents (Enzinger et al. 2002b, Murr et al. 1994, Oettl et
al. 1999).
Oxidative Stress and Antioxidant Activity within the
Atherosclerotic Plaque
Atherosclerosis is a very complex disease with many contributing factors. The
advanced plaques removed in endarectomy surgery represent a lifetime of lipid
deposition, low-level inflammation and oxidative stress. At this late stage of the disease
the biochemical morphology of plaques has diversified such that subclassifications are
required to describe the composition. This diversity is evident in the lack of consistent
trends found between the various markers measured. Significant correlations were rarely
seen in more then one plaque and trends found in the combined data set generally did not
hold true in individual plaques. It is therefore difficult to comment on any relationship
between the various markers.
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It is perhaps of more interest to note those things that one might have expected to
correlate which did not. There is little correlation between the various markers of
oxidation (Table 3); there is a relationship between DOPA and dityrosine across the
combined plaque data and in one plaque a correlation between TBARS and carbonyls;
otherwise there is no consistent pattern in oxidation levels. This suggests that there is
unlikely to be any oxidation “hotspots” within the plaque. An alternate explanation could
be the extensive remodelling that occurs in advanced plaque due to damage to structural
components, incorporation of thrombi and repair mechanisms (Stary et al. 1995). This
remodelling at late stages of plaque development could disrupt patterns of high localised
oxidative incidence.
Vitamin E and cholesterol correlated strongly in two plaques (Table 3), which
might be expected as vitamin E is lipid soluble; however, this relationship was not seen
in the combined plaque data. This suggests that, in the majority of the plaques tested,
vitamin E concentration is affected by something other than cholesterol content. It might
be hypothesised that the vitamin E is acting as an antioxidant and being depleted in this
manner. This would suggest a high radical flux and thus higher oxidation levels. This
may be illustrated in the negative correlation between vitamin E and DOPA; however,
measurement of lipid oxidation by TBARS shows a positive correlation with vitamin E.
This could imply a pro-oxidative role of vitamin E, particularly in areas of low radical
flux. Further investigation of the possibility of TMP occurring within atherosclerotic
plaque would require the quantification of co-antioxidants such as ascorbate and
ubiquinol-10. If low concentrations of these co-oxidants were to correlate with high
incidences of TBARS/Vitamin E it would strongly support the theory of TMP occurring
locally within the atherosclerotic plaque. Further to this, in areas of the plaque were co-
oxidants have not been depleted, vitamin E would be expected to still be functioning as
antioxidant.
Neopterin and protein correlated strongly in the two highly calcified plaques
(Table 3). Protein and neopterin both tended to be lower in the sections where
calcification was most marked. These lower values of neopterin and protein do not
manifest as an overall decrease in comparison to non-calcified plaques so it is likely that
these correlations are due to the calcium adding mass to the plaque sections without
directly affecting the quantity of protein present. A quantifiable measure of calcium
would be required to confirm this.
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The potential for neopterin to influence calcium deposition within the
atherosclerotic plaque has been speculated on (Gieseg et al. 2007). Little research has
been done in this area but both neopterin and 78NP have been shown to increase the
intracellular calcium concentration of monocytes from the human THP-1 cell line (Woll
et al. 1993). This increase is dependant upon the presence of extracellular calcium in the
medium. It is possible then that less calcification is seen in areas of high neopterin as this
induces uptake of calcium into cells.
Though there is no considerable difference in protein concentration between
calcified and non-calcified plaques; thrombosed plaques did show markedly higher
protein levels then those which are not thrombosed (Figure 42A). This is most likely due
to the incorporation of the highly proteinacious material, predominately platelets and red
blood cells, that the thrombus consists of. The higher values of dityrosine (Figure 42D)
and vitamin E (Figure 42E) seen in thrombosed plaques may also derive from this influx
of red blood cells. It has been demonstrated that dityrosine can be formed on intact red
blood cells during oxidant exposure in vitro (Giulivi and Davies 1993). It has also been
estimated that 3% of red blood cells undergo autooxidation daily, generating superoxide
that dismutases to hydrogen peroxide (Misra and Fridovich 1972), which would be
sufficient to produce significant amounts of dityrosine in red blood cells. Therefore it is
possible that inclusion of oxidised red blood cells can account for increased levels of
dityrosine within the thrombosed atherosclerotic plaques. Similarly there is a relatively
high content of vitamin E within the membrane of red blood cells (Simon et al. 1997) and
this could contribute to higher vitamin E concentrations seen in plaques with
incorporated thrombis.
Separation of the plaques into pre-, post-, and bifurcation areas did produce some
trends. The lower cholesterol content seen in pre-bifurcation sections (Figure 41A) could
be consistent with the proximal end of the plaque being the “leading edge” of new plaque
growth as this area of comparatively new plaque tissue would have had less time to
accumulate LDL. Similarly the trend towards lower dityrosine content in the pre-
bifurcation area of plaques (Figure 41B) could be indicative of “younger” tissue.
Alternatively, oscillatory and low shear stress typically occur at, and downstream of,
branch points in the artery (Chatzizisis et al. 2007). Low endothelial shear stress leads to
the amplified uptake, synthesis and permeability of LDL while at the same time
promoting oxidative stress and inflammation(Chatzizisis et al. 2007). This could explain
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the higher levels of cholesterol and dityrosine seen in the bifurcation and post-bifurcation
zones, which are the areas subjected to disrupted and low shear stress.
The trend of low dityrosine in the pre-bifurcation zone is not mirrored in the other
markers of protein oxidation which showed no significant difference between zones.
TBARS measurements showed an opposing trend of lower lipid oxidation in the post-
bifurcation section (Figure 41C). The lack of a similar trend to that of dityrosine in other
protein oxidation markers could be due to a lack of precision of the assays, preventing
such comparisons between zones being made. The opposing trend in TBARS is more
difficult to justify in the context of this theory. It could be that TBARS is more strongly
influenced by factors other then zoning.
Neopterin concentrations showed a trend of lower levels in the bifurcation zone
(Figure 41D) which could be accounted for by the presence of more activated
macrophages in the peripheral sections which have not yet become part of the necrotic
core. There is a tendency towards higher neopterin levels in the pre-bifurcation zone
which is consistent with the concept of this area being the newest area of plaque growth
with a greater content of activated macrophages that have not yet succumbed to the toxic
environment of the atherosclerotic plaque. However, it should be noted that when the
data is separated according to the method used for neopterin measurement the trend is
only apparent in those plaques measured by the TCA method (Figure 44B). It may be
that this effect is related to the generally smaller mass of sections in the pre-bifurcation
sections. This causes the homogenate of these sections to be more dilute. It is possible
that this dilution causes the neopterin in these sections to be less affected by the protein
interaction effects described earlier in the analysis development section of the discussion.
This would cause higher readings then that obtained in less dilute sections.
With the presence of activated macrophages it might be expected to find 78NP;
however, no significant quantity of 78NP was found within the atherosclerotic plaques
(results not shown). There are several possible explanations for its absence. It has been
suggested that 78NP is produced to protect macrophages from the oxidative environment
that they themselves generate (Gieseg et al. 2007). It may be that at this late stage of
plaque development the macrophages defensives have been exhausted and with the
depletion of 78NP also comes macrophage death. In order to assess this theory the 78NP
content of plaques in earlier stages of development would need to be measured.
Alternatively, it could be that the 78NP content of the plaques is oxidised during the
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homogenisation process. 78NP is relatively labile and the contents of atherosclerotic
plaques has been demonstrated to be highly oxidative (Smith et al. 1992); it may be
possible that the BHT and EDTA added to augment unwanted oxidative reactions
occurring during the experimental process was not sufficient to counteract this highly
oxidative environment.
While it may be tempting to use neopterin as an estimate of 78NP content, it is
not the only product of 78NP oxidation. The only mechanism for the in vivo production
of neopterin from 78NP, at present, is the reaction with hypochlorite. The scavenging of
hydrogen peroxide, superoxide and peroxyl radicals by 78NP produces 7,8-
dihydroxanthopterin (Duggan et al. 2002) (Figure 5). Unfortunately, 7,8-
dihydroxanthopterin is not fluorescent and is subsequently difficult to detect at low µM
levels in plaque. Thus any approximation made on 78NP content based upon its oxidative
products which fails to take into account 7,8-dihydroxanthopterin would be a substantial
underestimate.
While localisation of antioxidants and oxidative markers in sectioned plaques has
not been performed prior to this study, measurement of some of the markers of oxidation
and Vitamin E in plaque samples has been done previously. Vitamin E content of the
intima of advanced plaque has been measured resulting with an average concentration (±
SD) of 6.3 ± 4.8 mmoles/mole free cholesterol (Suarna et al. 1995). Our average across
all plaques of 1.5 ± 1.0 mmoles/mole of cholesterol is comparable, if somewhat lower.
This is most likely due to our use of all plaque material rather then restricting our
measurements to the intima only. TBARS have been previously measured in plaque
samples from carotid enderactomy surgery where the average TBARS value (± SD) was
36.4 ± 4.2 nmoles/g tissue by butanol abstraction and absorption methods (Nishi et al.
2002). Our results were considerably lower; 7.9 ± 5.8 nmoles/g plaque across all samples
using fluorescence detection with HPLC. The butanol/absorption method is known to
have problems with over-reading samples, due to the volatility of the solvents during
abstraction and the lack of specificity in the absorption readings (Halliwell and
Gutteridge 1999). These problems are overcome using HPLC fluorescence detection so it
is likely that our results are a more accurate measure of lipid peroxidation. DOPA and
dityrosine levels have been assessed in intima tissue from advanced plaques with mean
values (± SD) of 14.26 ± 3.80 and 4.75 ± 5.17 nmoles/g of tissue respectively (Fu et al.
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1998). We obtained remarkably similar means values (± SD) of 13.5 ± 9.7 nmoles/g of
plaque for DOPA and 4.6 ± 7.2 nmoles/g of plaque for dityrosine.
This study clearly demonstrated that markers of oxidative stress and inflammation
do vary across the length of an atherosclerotic plaque. This variation could allow for
localized incidences of high and low radical flux and microenvironments of depleted
antioxidants or areas in which the prooxidative actions of molecular components are
favoured. While consistent patterns between the markers were not readily evident, some
patterns may emerge with a larger data set where the plaques can be more effectively
grouped according to their compositional characteristics. There is no doubt that the
atherosclerotic plaque is a highly oxidative environment however the nature of this
environment varies within the plaque and between plaques which reflects upon the
complexity of the disease. Some variations can be related to the specific spatial
localization within the plaque in relation to the shear stress variations in the blood flow;
further investigations into the biochemical differences between these areas may provide a
better understanding of the growth and development of the atherosclerotic plaque.
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Appendix I
Table 4: Protein, cholesterol, neopterin and vitamin E concentrations for plaque
sections.
Protein
(mg/g
plaque)
Cholesterol
(umoles/g
plaque)
Neopterin
(nmoles/g
plaque)
Vitamin E
(nmoles/g
plaque)Plaque Section
Mean SEM Mean SEM Mean SEM Mean SEM
1 98.13 2.23 57.09 2.20 0.14 0.02 29.94 3.19
2 108.41 4.61 104.94 8.40 0.10 0.00 48.82 0.54
3 80.51 0.30 128.22 6.98 0.07 0.00 61.95 0.29
4 54.05 3.56 121.83 6.84 0.09 0.00 75.55 2.65
5 80.73 0.40 92.66 9.80 0.10 0.01 53.44 0.29
6 57.40 1.71 33.74 1.58 0.09 0.00 18.47 0.78
7 36.91 0.57 23.07 1.17 0.07 0.00 8.84 0.18
IH120704
A
8 46.27 0.64 23.86 1.37 0.03 0.00 22.41 0.63
1 93.89 4.11 25.54 5.37 0.31 0.01 11.90 1.24
2 80.32 0.69 88.78 2.54 0.47 0.01 57.66 3.11
3 82.77 1.37 93.48 3.54 0.10 0.00 37.35 1.58
4 68.33 3.52 116.46 13.05 0.17 0.02 5.75 0.38
5 84.83 4.08 60.19 3.85 0.08 0.01 17.99 0.41
6 93.27 3.71 91.27 4.48 0.09 0.01 13.74 0.02
HW290304
B
7 128.12 1.64 90.52 2.55 0.25 0.01 41.55 3.10
1 70.10 1.41 22.16 2.54 1.86 0.03 45.04 3.14
2 55.09 1.85 50.54 1.41 1.02 0.01 100.18 0.54
3 57.45 1.49 56.59 4.32 1.11 0.02 100.22 1.06
4 67.35 1.43 78.87 2.84 2.32 0.06 92.96 0.66
5 54.19 5.90 53.12 0.95 1.06 0.02 116.88 2.29
6 78.49 5.74 88.27 1.26 2.01 0.02 89.32 4.45
WC210604
C
7 67.17 4.30 56.12 2.01 1.73 0.04 63.48 1.48
1 100.50 2.93 32.53 1.39 0.04 0.00 131.90 7.96
2 82.19 2.20 49.54 4.29 0.04 0.00 123.44 13.92
3 113.16 2.65 37.29 1.45 0.04 0.00 98.39 1.47
4 73.65 0.40 39.62 5.92 0.05 0.00 84.60 6.57
5 94.40 1.24 66.19 1.63 0.04 0.00 283.69 13.80
MS200405
D
6 88.93 4.81 61.05 5.43 0.04 0.00 173.00 4.40
1 133.31 14.20 24.32 3.42 2.18 0.04 36.80 9.58
2 52.42 3.70 43.10 1.07 0.62 0.01 73.01 2.30
3 48.01 0.76 16.10 0.92 0.42 0.03 34.05 1.80
4 156.12 31.49 31.22 2.84 2.21 0.10 41.84 6.25
5 50.68 2.85 22.30 0.00 0.57 0.02 33.17 1.15
ES020407
E
6 133.84 29.41 20.75 1.77 1.58 0.01 33.12 1.59
1 114.80 6.80 39.87 1.30 0.57 0.02 149.31 1.32
2 141.62 1.27 69.77 0.64 0.76 0.03 185.26 13.29
3 131.47 2.36 35.43 2.01 0.79 0.05 132.62 20.28
4 120.73 10.75 73.57 12.11 1.26 0.03 187.91 3.48
5 160.91 5.72 71.52 2.55 1.13 0.07 165.01 7.11
GP050407
F
6 172.44 5.18 64.77 0.51 1.02 0.06 79.57 3.16
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Table 5: Carbonyls, Dityrosine, DOPA and TBARS concentrations for plaque
sections.
Carbonyls
(nmoles/g
plaque)
Dityrosine
(nmoles/g
protein)
DOPA
(nmoles/g
plaque)
TBARS
(nmoles/g
plaque)Plaque Section
Mean SEM Mean SEM Mean SEM Mean SEM
1 368.85 187.28 0.85 0.17 18.29 1.33 3.69 2.75
2 294.05 76.76 1.82 0.15 17.79 0.51 13.19 6.85
3 245.93 38.12 1.54 0.05 14.68 0.91 8.31 10.66
4 471.43 42.10 0.26 0.02 11.63 1.45 10.04 7.35
5 391.19 115.20 0.13 0.00 17.47 0.71 10.37 13.27
6 327.38 41.24 0.11 0.01 13.49 1.74 7.24 16.25
7 231.43 58.76 0.00 0.00 13.13 2.67 4.82 1.67
IH120704
A
8 151.43 25.93 0.00 0.00 18.81 2.06 2.15 1.12
1 163.23 26.03 1.17 0.01 56.92 11.29 0.84 0.83
2 212.01 27.47 5.11 0.25 25.96 0.29 4.77 0.75
3 165.37 19.29 10.93 0.58 25.81 0.45 13.06 1.27
4 76.42 16.13 42.75 1.62 32.76 1.57 12.15 2.81
5 141.56 10.53 5.08 0.28 29.44 1.95 7.05 2.03
6 55.60 21.14 8.28 0.58 11.15 1.43 12.28 1.15
HW290304
B
7 171.81 31.96 7.99 0.87 16.01 4.59 4.18 0.37
1 521.00 50.27 0.00 0.00 5.58 0.66 0.44 0.44
2 188.70 23.56 0.60 0.03 10.00 1.52 3.25 0.07
3 221.98 50.07 1.87 0.10 4.76 0.53 10.26 0.67
4 295.19 76.91 1.18 0.15 3.27 0.93 6.68 0.85
5 248.03 65.96 0.35 0.05 3.19 0.25 8.60 0.80
6 304.90 50.23 1.71 0.08 5.95 0.56 2.23 0.30
WC210604
C
7 232.80 67.45 0.66 0.05 1.48 0.16 0.22 0.07
1 660.90 247.10 0.00 0.00 3.80 0.19 12.78 3.40
2 299.47 228.67 10.67 0.67 35.50 13.45 6.13 1.49
3 581.77 65.39 9.70 1.02 19.30 1.69 10.87 1.44
4 468.92 56.27 15.66 0.48 22.99 1.47 6.27 1.13
5 347.48 81.05 16.02 0.37 2.22 1.39 6.66 1.06
MS200405
D
6 311.72 135.44 1.14 0.05 9.21 4.56 0.08 0.08
1 338.52 193.02 0.00 0.00 13.92 9.17 24.94 1.53
2 200.71 64.96 0.00 0.00 3.20 2.25 10.80 1.52
3 56.36 41.51 0.00 0.00 4.22 0.58 13.54 2.49
4 453.51 93.19 0.00 0.00 3.93 2.21 10.20 2.45
5 255.05 109.38 0.00 0.00 6.32 1.75 17.82 3.73
ES020407
E
6 352.94 300.23 0.00 0.00 13.96 7.30 8.35 1.41
1 300.54 9.82 6.08 0.41 6.20 0.88 11.63 1.72
2 401.12 76.91 9.59 0.27 12.35 2.76 13.55 2.54
3 334.54 66.55 9.96 2.03 8.97 1.11 6.03 0.74
4 277.78 35.77 11.75 4.29 10.76 0.87 23.65 3.50
5 693.88 40.82 10.33 2.21 12.19 0.86 22.22 0.47
GP050407
F
6 331.54 131.63 7.44 1.51 9.99 0.88 15.87 0.38
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Appendix II
The following papers are entitled “Dissociation of neopterin and 7,8-
dihydroneopterin from plasma components before HPLC analysis” and “Potential to
inhibit growth of atherosclerotic plaque development through modulation of macrophage
neopterin/7,8-dihydroneopterin synthesis”. The first was generated entirely from this
Masters thesis; the second includes one figure (Figure 2) that was generated from data
produced as a part of this Masters thesis.
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